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10 | Introduction
Cardiovascular disease remains the major cause of death worldwide (1). Most acute cardio-
vascular events, such as myocardial infarction and stroke, are a consequence of atherosclerosis 
in which plaques form due to chronic inflammation and lipid accumulation in the vessel wall. 
Cardiovascular events can be triggered by rupture of an atherosclerotic plaque, resulting in 
arterial thrombosis and concomitant occlusion of the vessel and a subsequent acute ischemic 
event (Figure 1). Plaques with a high risk of rupture are called vulnerable plaques, while 
plaques with a low risk of rupture are called stable plaques. These stable plaques may only 
cause symptoms when luminal obstruction is significant, limiting bloodflow. Traditionally, the 
burden of atherosclerotic disease is estimated from the percentage of stenosis detected by 
various imaging techniques, such as coronary angiography or Computed Tomography (CT). 
However, vulnerability depends on plaque composition. A vulnerable plaque usually exhibits 
characteristics such as a large necrotic core, infiltration of inflammatory cells, a thin fibrous 
cap, neovascularization, and intra-plaque haemorrhage (2). Although non-invasive imaging 
techniques, such as CT and MRI can assess certain aspects of plaque composition, such as 
calcification (Figure 2), these techniques fail to detect non-stenotic – possibly vulnerable – 
plaques. Patients without stenosis could therefore still present with vulnerable atherosclerosis 
and consequently be at risk of cardiovascular events. 
Figure 1 | Cartoon of plaque rupture in a coronary artery followed by myocardial infarction. Rupture of the 
plaque leads to arterial thrombosis, which prevents blood and therefore oxygen from flowing to downstream 
tissue. This leads to ischemia in these tissues, which results in death of the tissue if the artery is not unblocked 
in time. From Patient Information: Atherosclerosis (The Basics). In: Basow DS, ed. UpToDate, Waltham, MA; 2013. 
with permission from the publisher. Copyright © 2013 UpToDate, Inc. 
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Timely detection of plaque, and differentiation between stable and rupture-prone plaque 
would allow targeted treatment and prevention of potentially life-threatening cardiovascular 
events. Current imaging methods used for plaque detection are methods such as CT, ultrasound, 
or Magnetic Resonance Imaging (MRI) (Figure 2). CT and ultrasound give information on 
luminal narrowing or calcification, MR imaging can give information on stenosis and plaque 
composition. A luminal stenosis degree of 50–70% or higher is considered significant and may 
be an indication for revascularization, such as percutaneous coronary intervention. However, 
the majority of atherosclerotic lesions (68%) responsible for the initiation of acute myocardial 
infarction do not cause major obstruction of the coronary lumen with a stenosis degree below 
50% (3-6). If the decision to treat is made only based on degree of stenosis, we therefore miss a 
large part of culprit plaques. 
Visualisation of plaque components which are characteristic of vulnerable plaque should 
therefore be included. However, current techniques are either invasive, have limited resolution, 
or the identified features of vulnerability were not sufficient to predict an event. MRI can give 
additional information on plaque composition, most notably intra-plaque haemorrhage, but is 
due to its resolution mostly limited to the carotid arteries. CT and ultrasound have additional 
prognostic value by visualising features like plaque calcification. The prognostic value of 
imaging can be improved further by visualizing other features of vulnerable plaque.
Figure 2 | Shows traditional imaging methods used for plaque visualization. CT angiography and 
ultrasound give information on luminal narrowing or calcification (calcification indicated by white arrow). 
MR imaging can give information on plaque composition, but often lacks the resolution required to give this 
information for small plaques, especially in the coronary arteries. From (7). 
Inflammation is a major hallmark of atherosclerosis and a consistent predictor of cardiovascular 
risk. Moreover, inflammation plays a major role in all stages of the disease, and the degree of 
inflammation is linked to plaque vulnerability (8,9). Therefore, detection and assessment of the 
severity of plaque inflammation may help to identify patients at risk of future cardiac events. 
Currently, evaluation of blood biomarkers for inflammation such as high-sensitive C-Reactive 
Protein (hsCRP) (10) provides information on patient-wide inflammatory status. However, it 
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does not give an indication on the status of individual plaques. An imaging method which 
both detects plaque localization and provides information on the risk of rupture could result in 
significant advances in patient treatment.
 
Nuclear medicine has the potential to fulfil this need because it combines specifically targeted 
radiolabelled tracers (radioligands) with highly sensitive and accurate detection methods, like 
Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography 
(PET) (11). Radiolabelled tracers directed towards certain targets are being developed for that 
purpose. After injection of such tracers or radioligands, SPECT or PET can be used to detect 
the location of the radioactivity, indicating the target’s localization by which the cell type or 
process of interest can be followed (Figure 3 & Box 1). Because highly sensitive and quantitative 
data can be acquired with these techniques, an assessment of the abundance of the target 
molecule in a specific location can be made.
Figure 3 | Schematic representation of a radioligand and its target. SPECT and PET can be used to detect 
the radiation emitted by the radionuclide, which therefore indicates the location of the target, and therefore 
the location of the cells on which this target is expressed. 
 
Nuclear imaging of inflammation was first explored with 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG) (12). This molecule is taken up by metabolically active cells, including metabolically 
active macrophages in plaques. In this manner, 18F-FDG has successfully been used to visualize 
plaque and quantify the level of inflammation in plaques (13,14). However, uptake in the 
metabolically active myocardium severely hinders plaque detection in the coronary arteries 
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(15,16). Moreover, uptake in other metabolically active cells in the vasculature can complicate 
plaque visualization. Therefore, novel radioligands are required which more specifically 
target inflammatory cells, and which suffer less from interference from radioactivity uptake in 
surrounding tissues.
Box 1 | A schematic representation of the imaging process of a radioligand.
A) A tracer or ligand is radiolabelled with a radionuclide, for example 111In (Location indicated by 
‘R’). This is the molecular formula of DANBIRT, one of the ligands evaluated in this thesis. B) The 
radioligand is intravenously injected into a subject like a patient or an animal model. The radioligand 
is distributed throughout the body and binds to its respective targets. Excess, unbound, radioligand 
is cleared by excretion via e.g. the kidneys and bladder or via the intestines. C) The radionuclide 
attached to the ligand emits radiation when it decays to a stable form, γ-rays are emitted by 111In. 
The γ-rays are detectable with Single Photon Emission Computed Tomography (SPECT) imaging 
systems. SPECT relies on physical collimation, in which the γ-rays cannot penetrate the (usually) 
lead collimator in front of the detector. Only y-rays travelling in the same direction as the collimator 
slits will reach the detector, therefore providing information on the source of the radiation. Here you 
see an image of a traditional parallel hole collimator. D) In this thesis we use a pinhole collimator, 
which greatly enhances the spatial resolution. E) By registering γ detections in detectors, the origin 
of the γ-rays can be estimated. If enough of these detections are registered, a single point of origin 
can be estimated. F) Based on these estimations, an image can be reconstructed indicating where 
the radiation originates from, which indicates where the radioligand and therefore the radioligand 
target is located. The location of the radioligand target in the body can be assessed by coupling 
SPECT to an anatomical imaging modality like Computed Tomography (CT) or Magnetic Resonance 
Imaging (MRI). Because PET and SPECT yield a quantifiable signal, the abundance of the radioligand 
target can estimated. Image adapted from (76).
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Thesis outline
This thesis work describes the assessment and evaluation of novel and existing radioligands 
for a new application: use in plaque detection and characterization. Moreover, novel imaging 
protocols, which might improve patient stratification, are discussed. Figure 4 provides a 
schematic visualisation of the research aims of this thesis.
In Chapter 2 the considerations involved in nuclear imaging of plaques are discussed. We 
reflect on animal models applied, technical aspects, radioligand development, and provide a 
future outlook.
In Chapter 3 we show the evaluation of a novel imaging ligand, [111In]In-DANBIRT, targeted 
to the Leukocyte Function-associated Antigen-1 (LFA-1) for plaque detection. We tested 
the radioligand in vitro in human and mouse plaque tissue, and in vivo in a mouse model of 
atherosclerosis.
Somatostatin Subtype Receptor 2 (SST2) is a promising target for atherosclerotic plaque 
visualization. In Chapter 4 we describe the assessment of [111In]In-DOTA-JR11, a receptor-
antagonistic radioligand targeting SST2. We evaluated the compound in vivo in a mouse model 
of atherosclerosis, and in vitro in both mouse and human plaque tissues.
A novel dual isotope imaging approach for plaque characterization is discussed in Chapter 5, in 
which we describe the evaluation of [111In]In-DANBIRT and [99mTc]Tc-DEMOTATE 2, a radioligand 
targeting SST2, in human plaque tissues. This approach could be used to simultaneously 
visualize all inflammatory cells as well as a subset of pro-inflammatory macrophages.
Chapter 6 describes investigations in vitro in human plaque material to examine how the 
targets of a number of the most promising radioligands available are distributed throughout 
different plaque phenotypes, and how binding of these radioligands compare to each other in 
these tissues.
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 15
15A Road to Improved Diagnostics – Imaging Inflammatory Cells in Atherosclerosis | 
1
Figure 4 | A cartoon depicting the features of vulnerable plaque, and the research topics of this thesis: 
detection of plaque based on imaging of inflammation, development of tools to assess the inflammatory 
status of plaque, and interpretation of radioligand binding in plaque. The aims can only be achieved with 
state-of-the-art equipment, and optimization of the experimental approach such as animal models and 
imaging protocols. 
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Abstract
This review addresses nuclear SPECT and PET imaging in small animals in relation to the 
atherosclerotic disease process, one of our research topics of interest. Imaging of atherosclerosis 
in small animal models is challenging, as it operates at the limits of current imaging possibilities 
regarding sensitivity and spatial resolution. Several topics are discussed, including technical 
considerations that apply to image acquisition, reconstruction, and analysis. Moreover, 
molecules developed for or applied in these small animal nuclear imaging studies are listed, 
including target-directed molecules, useful for imaging organs or tissues that have elevated 
expression of the target compared to other tissues, and molecules that serve as substrates for 
metabolic processes. Differences between animal models and human pathophysiology that 
should be taken into account during translation from animal to patient as well as differences 
in tracer behaviour in animal versus man are also described. Finally, we give a future outlook 
on small animal radionuclide imaging in atherosclerosis, followed by recommendations. The 
challenges and solutions described might be applicable to other research fields of health and 
disease as well.
Keywords: Mice, Nuclear imaging, SPECT, PET, Atherosclerosis
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Introduction
Small animal radionuclide imaging: nuclear imaging using Single Photon Emission Computed 
Tomography (SPECT) or Positron Emission Tomography (PET) allows high-sensitivity and 
(semi-) quantitative imaging of physiological processes or molecular targets in vivo. Before 
clinical application, preclinical evaluation of novel radiotracers is a requisite to assess tracer 
characteristics such as in vivo tracer kinetics, target specificity, stability, and biodistribution. 
This is greatly facilitated by the wide-spread use of small animal models of disease as well as 
the development of state of the art small animal SPECT and PET systems, which allow tracer 
examination up to sub-mm resolution (1-6). However, preclinical nuclear imaging of small 
animals comes with a particular set of challenges and opportunities different from clinical 
nuclear imaging.
Atherosclerosis: The challenges and opportunities of small animal imaging become apparent 
in e.g. atherosclerosis imaging. Atherosclerosis is an inflammatory disease in which fatty plaques 
might occlude an artery through continued lipid deposition or sudden rupture of vulnerable 
plaques. Occlusion of an artery can lead to myocardial infarction, stroke, or limb ischemia. 
Early detection and characterization of atherosclerosis is therefore important, but remains 
problematic. Many imaging techniques such as contrast enhanced Computed Tomography 
(CT) focus on degree of stenosis, but fail to identify vulnerable plaques. Functional imaging of 
biological processes involved in plaque development or progression may identify and localize 
plaques at risk of rupture. Moreover, the characteristics of a vulnerable plaque, such as the 
presence of intraplaque haemorrhage, a large influx of inflammatory cells, neovessel formation, 
or a thin fibrous cap (7), provides ample possibilities for nuclear imaging. Yet, when studying 
novel tracers that might fulfil this need, research teams are faced with challenges. Differences 
between animal models of atherosclerosis and the human pathophysiology can make imaging 
results difficult to interpret. Furthermore, the small size of the plaques in small animal models, 
as well as the low and diffuse density of targets in a plaque, can severely complicate the 
evaluation process including quantification options in vivo.
Nuclear imaging of atherosclerosis: 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) has been 
extensively studied for the detection and quantification of inflammatory cells in atherosclerosis 
(8,9), and has been shown an independent predictor of recurrent events after stroke (10-12). 
Moreover, differentiation between different plaque phenotypes in the carotid arteries was 
successfully investigated using this tracer (13). However, unspecific uptake of 18F-FDG, especially 
in the metabolically active myocardium, limits its use to detect plaques in coronary arteries. As 
such more specific tracers are urgently needed.
In this review, we describe small animal radionuclide imaging with a strong focus on applications 
in atherosclerosis. We discuss differences between the pathophysiology of human and mouse 
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atherosclerosis, related technical aspects and challenges of small animal radionuclide imaging, 
as well as atherosclerosis tracer development and evaluation. Moreover, we discuss the future 
outlook and give recommendations.
Considerations on models of atherosclerosis
Animal models of atherosclerosis: A number of atherosclerotic animal models have been 
developed, as reviewed in (14). In short, porcine and primate models resemble human 
atherosclerosis best, yet are costly to maintain and are less established with regard to genetic 
modification. The plaques in rabbit models resemble human plaque less, as rabbit plaques 
mainly contain lipids. Rabbit models have certain advantages over mouse models, including the 
diameter of the abdominal aorta being similar to human coronary arteries and less subjected 
to movement. However, rabbit models are less frequently used since the introduction of the 
Apolipoprotein E deficient (ApoE-/-) and low density lipoprotein receptor knock-out (LDLR-/-) 
(KO) mouse models (15). Most atherosclerosis studies therefore use murine models, as mouse 
plaques develop faster than rabbit plaques, the mouse models are well characterized, have low 
costs, and are widely available. Recent developments like clustered regularly interspaced short 
palindromic repeats/Cas9 (CRISPR/Cas9) targeted genome editing to create KOs (16), and pro-
protein convertase subtilisin/kexin type 9 (PCSK9) injection to rapidly induce atherosclerosis 
(17), have created new opportunities in modelling human-like atherosclerotic disease in 
mice. We refer to (18) for a more extensive review of mouse models of atherosclerosis. Besides 
advantages in using atherosclerotic mice, there are several considerations to be taken into 
account when choosing a mouse model and interpreting imaging results. 
Plaque location and composition: Like in humans, atherosclerosis in mice is multifocal and 
locates in specific regions of the vasculature, determined by the hemodynamic environment 
(19). Pre-clinical imaging studies generally study plaques located in the inner curve of the 
aorta, the carotid arteries, and brachiocephalic artery, while translating their results to human 
coronary disease. Plaque composition as well as plaque stability or vulnerability differ between 
mice and men; differences in lipid metabolism lead to different lipid profiles related to the ratio 
between high, very low, and low density lipoprotein (HDL, VLDL, and LDL) (14,20). Moreover, 
thin caps or intraplaque haemorrhage are rare in traditional mouse models, whereas they are 
characteristic of human vulnerable atherosclerosis (21), and plaque rupture is rarely seen in 
commonly used mouse models (22). To create a mouse model with plaque rupture, double 
knock outs (23,24) or invasive experimental interventions are required, which arguably do not 
mimic human plaque rupture mechanisms (25). 
Immune subsets: Inflammatory cells are often used as imaging targets, because of the 
important role they have in plaque formation and progression. Yet, it is reported that human 
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and mouse macrophage subsets differ (26,27), which therefore makes validation in human 
tissue necessary.
Despite these differences between human and murine atherosclerosis, mice are valuable 
in testing radiotracers, as processes like angiogenesis and inflammation are present in 
mouse plaques. Therefore, mice can be used for proof of concept studies, or to assess tracer 
behaviour in vivo. Moreover, ex vivo validation by gamma-counting, autoradiography, and 
immunohistochemistry allows better quantification of radiotracers. However, for reasons 
discussed above, translating results obtained in mouse models to expected human results 
should be done with caution.
Technical developments and applications in small animal 
radionuclide imaging
Nuclear imaging of mouse and human plaques: SPECT and PET can both provide very high 
sensitivity, even suitable for imaging of very small quantities of radiotracers (nM-pM range), 
enabling investigation of specific cells or pathophysiological processes. Developments in these 
systems for small animal imaging and in processing of imaging data allow better examination 
of novel radiotracers. Moreover, preclinical systems allow high resolution and sensitive 
examination of human tissues (28,29). When imaging mouse atherosclerosis challenges 
become apparent: high spatial resolution is crucial in small murine plaques. The largest murine 
plaques are located in the aorta, which has a diameter of ~1mm. High sensitivity is however 
also very important, as these small plaques contain relatively few target cells, on which receptor 
expression can be low compared to other disease models such as tumour models. Here we 
highlight a number of developments in imaging and image processing, see (30-36) for more 
extensive reviews on nuclear imaging methods. 
Preclinical SPECT: SPECT systems require a collimator to obtain directional information on 
gamma rays emitted from within the animal or patient sample to be imaged. Traditional clinical 
SPECT systems generally use a parallel hole collimator, which limits resolution and sensitivity 
in comparison to clinical PET systems that do not require a collimator (Table 1) (37). The choice 
of collimator heavily depends on the imaging task at hand because of the classic trade-off 
between resolution and sensitivity in collimator design. Regarding spatial resolution, major 
improvements have been made in preclinical SPECT by the introduction of pinhole cameras, 
in which magnified projection data can be acquired by choosing the right positions of the 
pinholes between the scintillation crystal and the animal (38), enabling sub-mm resolutions 
(Table 1 and Figure 1). Such high spatial resolutions can be achieved by decreasing the diameter 
of the pinhole, but come with the obvious trade-off of lower sensitivity. Multipinhole cameras 
combat the very low sensitivity of a single pinhole (39), and can reduce or even eliminate the 
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Table 1 | Shows a tabulated overview of properties of clinical and preclinical PET and SPECT. 
Small Animal Scanners Standard Clinical Scanners
Resolution  
[mm]






SPECT Tc-99m 0.38–0.76 (83) 0.07–0.39 (83) ~10 ~0.01
SPECT In-111 0.71–0.85 (83) – – ~0.01
Pinhole PET F-18 <0.85* (84) 0.37 (84) – –
Coincidence PET F-18 1.61–2.34 (39) 1.19–6.72 (39) 6.4 (46) 1.33–2.29 (85)
Coincidence PET Ga-68 2.19 (86), 2.2 (87) – 7 (46) –
* Resolution was determined by visual assessment of a Jaszczak phantom instead of measuring the FWHM of a line source. 
** Values for sensitivity should be interpreted with care, as no standard method exists to directly compare SPECT and 
coincidence PET sensitivity quantitatively. When covering a FOV the size of a PET FOV, the effective sensitivity of SPECT 
could well be several factors lower.
Figure 1 | A) illustrates the principle of pinhole imaging. The collimator can be placed close to the source 
of radiation in preclinical imaging, resulting in a magnifying effect on the detector. The limited sensitivity 
is improved by using multiple pinholes and different pinhole geometries. Clinical SPECT mostly uses 
parallel hole collimators, which directly limits spatial resolution. Pinhole magnification can also achieve 
a higher spatial resolution for positron emitting isotopes In comparison to traditional coincidence PET 
(Image reproduced from thesis O. Ivashchenko, LUMC, ISBN 978-94-92516-35-0). B) shows the principle of PET 
coincidence detection. Two opposing detectors simultaneously measure a gamma photon providing the 
line along which the positron annihilated with an electron. This line does not coincide with the location 
the positron was emitted, because the positron travels a finite range before it annihilates. Especially for 
high energy positrons, e.g. 68Ga (mean positron range of 2.9 mm (52)), the positron range may limit spatial 
resolution in both pinhole PET and coincidence PET. Image adapted with permission from (131). 
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need of rotating detectors or movement of the bed if only a small field of view (FOV) is required 
to answer the research question (40,41). This greatly improves temporal resolution, offers the 
possibility of 3D gated imaging of the heart, and enables imaging of fast tracer kinetics (42). 
High sensitivity collimators have been developed (43), but the sensitivity of SPECT systems 
remains limited in comparison to that of PET because of the relatively low fraction of photons 
transmitted through the collimators.
Preclinical PET: The sensitivity of PET scanners is at least an order of magnitude higher than 
SPECT cameras (>10 times (44), see Table 1), since no physical collimator is needed. In preclinical 
PET (ring diameter <20 cm), the resolution is mostly limited by the positron range and the 
size of the detector elements. For low energy positron emitters (18F) both factors limit spatial 
resolution, for high energy positron emitters (68Ga) the positron range is the main limiting 
factor (44-46). 
Positron emitting radionuclides can be imaged with a traditional coincidence based PET 
system and also with special pinhole collimation (47,48). Traditional ring PET systems can 
achieve a better image quality in very low count rate studies, for higher count rate studies a 
multi-pinhole system may yield higher quality images due to the higher spatial resolution that 
can be achieved by pinhole magnification. 
Hybrid Imaging: Use of hybrid systems, providing an anatomical reference by (contrast-
enhanced) CT or MRI (1,2,39,49), are crucial in atherosclerotic mouse studies because the small 
plaques are located close to other tissues. MRI has the major advantage of providing soft tissue 
contrast, which is crucial to distinguish arteries from surrounding tissue. However, the better 
resolution and faster scanning time of CT make this method preferable in many instances, 
especially if contrast agents can be used. Moreover, CT provides direct means for attenuation 
correction (50), whereas an MR image is usually segmented into different tissue classes to 
obtain an estimate of the amount of attenuating material. New opportunities are opened by 
the combination of more modalities, such as optical tomography, or integrating PET and SPECT 
to allow dual-tracer imaging. Moreover, dual tracer imaging is also explored in PET (reviewed in 
51), allowing further possibilities in tracer imaging.
Preclinical versus clinical imaging: Preclinical SPECT can achieve a higher spatial resolution 
than preclinical PET platforms, whereas this is the other way round in clinical imaging (see Table 
1). The higher resolution of preclinical SPECT often makes it the imaging method of choice for 
imaging of atherosclerotic mice because of the small sized plaques. Preclinical visualisation of 
plaques with PET isotopes can further be complicated by positron range, as this can exceed the 
size of a plaque (e.g. 68Ga has a mean positron range of 2.9 mm (52)). Image quality of clinical 
PET can be improved by Time of Flight (ToF), which reduces image noise by incorporating the 
time difference of the detected annihilation photon pair in the reconstruction. Clinical systems 
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obtain a timing resolution of ~300 ps (53). In a preclinical system image quality did not improve 
for a timing resolution of 260 ps (54). Another difference comprises the small deviation from 
180° between the annihilating photon pair (noncollinearity) that reduces the spatial resolution 
for systems with a larger PET ring diameter. This becomes a major limiting factor in clinical PET 
(44), whilst this effect is negligible in small animal PET. Also, in clinical practice gated imaging 
is used to improve image quality of moving structures like the heart and its coronary arteries 
(55,56). A trade-off has to be made between scan time and image quality to obtain sufficient 
count statistics in each gate. Using image registration techniques, motion-free static images 
can be obtained without affecting count statistics (57). This application is thus not commonly 
applied in preclinical imaging. Finally, the high sensitivity and simultaneous acquisition of all 
projection angles in whole body PET makes it superior over SPECT with regard to temporal 
resolution, as the time needed to obtain sufficient counts directly determines scanning time.
Image reconstruction: Virtually all preclinical and clinical images are reconstructed by an 
iterative reconstruction algorithm. These algorithms rely on a model of the physics in the 
imaging process, where improvement of the model improves the quality of the reconstructed 
images. For example, spatial resolution can be improved by including the point spread function 
in the model (58). Monte Carlo based methods can improve scatter estimation and can include 
depth of interaction effects for PET in the iterative reconstruction (59,60). Efficient algorithms 
can reduce reconstruction time while preserving image quality even in low count studies (61). 
Quantification: Besides visualizing the radiotracer distribution, most atherosclerosis imaging 
studies perform (semi-) quantitative Volume Of Interest (VOI) or voxel based measurements. 
This is expressed in percentage injected dose per gram, standardized uptake value, or target 
to background ratio (%ID/g, SUV, or TBR). It is important to consider against which background 
a target tissue is visualized. Plaque to blood ratio is usually a useful TBR in atherosclerosis 
imaging, as blood signal can interfere with plaque signal. The myocardium would be a suitable 
background when using a radiotracer such as 18F-FDG in the coronary arteries. Images can be 
quantified when applying a suitable predetermined calibration factor to convert counts per 
volume to activity per volume (Bq/ml). Attenuation and scatter correction is less important in 
preclinical imaging due to the smaller amount of attenuating material, but their application 
still improves quantification accuracy (50,62-64). When imaging structures with sizes around or 
below the resolution of the camera, like plaques in mice, it is important to realize that partial 
volume effects can cause a substantial underestimation of the true value (65,66). This makes 
absolute quantification accuracy dependent on the imaging task. Numerous compensation 
techniques for partial volume effects have been described (67), but none have been validated 
or used in preclinical arthrosclerosis imaging yet.
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Radiotracers and their targets
Radiotracers and radionuclides: Radiotracers should target processes relevant to disease, 
which in atherosclerosis are e.g. inflammation, endothelial dysfunction, neovascularization, 
hypoxia, cell death, or microcalcification. Moreover, the target should ideally be abundantly 
expressed and specifically localized in plaques and not in surrounding tissues. Also, blocking 
studies should be performed, as non-specific uptake in the arterial wall could complicate plaque 
visualization. Radiotracers need to be stable in vivo without pharmacological or toxic effects, 
and should be labelled with an appropriate radionuclide, matching the pharmacokinetics of 
the tracer. Radiotracers labelled with short-lived PET radionuclides should have a fast clearance 
to prevent blood signal from interfering with plaque visualization. Moreover, it is advantageous 
if radiotracers show rapid diffusion into tissues. If a radiopharmaceutical is being developed 
with the objective of use in humans, then the radionuclide intended for human use should 
be used in the animal studies if at all possible as this will simplify translation of preclinical 
data. In some cases, however, the use of a different radionuclide for some of the preclinical 
studies is unavoidable or even preferable, as it can be preferred to label radiotracers with SPECT 
radionuclides for high-resolution preclinical evaluation versus PET radionuclides for clinical use. 
Beyond 18F-FDG: 18F-FDG PET has shown major promise in atherosclerosis imaging (8). 18F-FDG, 
being a glucose analogue, is taken up by metabolically active cells such as macrophages in 
plaque, and can therefore be used for PET imaging of atherosclerosis. Plaque inflammation can 
be quantified using 18F-FDG, plaques can be monitored over time, and the effect of treatment 
can be visualized (68). However, unspecific myocardial uptake of 18F-FDG limits the applicability 
of imaging in coronary artery disease. Therefore, novel radiotracers targeting different disease 
processes with a higher specificity are being developed and evaluated. Table 2 lists a number 
of radiotracers and their targets tested in preclinical in vivo imaging studies in the past 10 years, 
and potential clinical follow up studies. Figure 2 includes 2 cases in which the possibilities and 
challenges of small radionuclide imaging of atherosclerosis are exemplified. Reference (69) 
reviews older studies performed with PET. 
Currently, Pentixafor (70,71), DOTATATE (72,73), and NaF (reviewed in 9) show very promising 
results in patients. Recent successful mouse studies have been performed on other tracers 
such as DANBIRT (74), Tilmanocept (75), or Maraciclatide (76). Direct comparisons between 
radiotracers as performed in (72), are lacking however, which makes it difficult to see where 
radiotracers can complement each other, or which radiotracer is most suitable for different 
aspects of plaque visualization.
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Table 2 | shows radiotracers applied in a selection of preclinical in vivo atherosclerosis imaging studies from 








Inflammation Macrophages FDG 18F (13) (11) Retrospective, n=513
  Macrophages, SST2  DOTATATE 68Ga (72)  (88) Retrospective, n=70 
(89) Prospective, n=20 
(73) Prospective, n=42

















Macrophages, CXCR4 Pentixafor 68Ga (70) (71) Retrospective, n=38 
(94) Retrospective, n=51
  Leukocytes, LFA-1 DANBIRT  111In (74)  
  Macrophage  
proliferation 
FLT 18F (95)  
  Chemokine 
receptors
DOTA-vMIP-II 64Cu (96,97)  
  DOTA-DAPTA 64Cu (98)  
LOX-1 Liposome-LOX-1 111In (99)  
    Camelid antibody 
fragment
99mTc (100)  






  (101) Prospective, n=15 
(102) Prospective, n=32 
(103)









Apoptosis Apoptosis &Necrosis AnxAF568 
Hypericin
99mTc, 124I (106)  
  Apoptosis Duramycin 99mTc (107)  
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Angiogenesis αvβ3 integrin NC100692
99mTc (109)  
    NOTA-RGD 68Ga (110) (110) Prospective, n=4
    Flotegatide 18F (111)  
  Galacto-RGD 18F (112) (113) Prospective, n=10
NOTA-3-4A 64Cu (114)
    Maraciclatide 99mTc (76)  
    IDA-D-[c(RGDfK)]2
99mTc (115)  
  VEGF 1 & 2 scV/Tc 99mTc (112, 
113)
 
Proteolysis MMP activation RP805 99mTc (114, 
115)
 
    RP782 111In (116, 
117)
 





P-selectin P-selectin antibody 64Cu (123)  
  Fucoidan 68Ga (124)  





    4V 18F (129)  
Hypoxia Redox FMISO 18F (130)  
Abbreviations: SST2, somatostatin receptor subtype 2; MR, Mannose Receptor; FR, Folate Receptor; CXCR4, C-X-C Chemokine 
Receptor type 4; LFA-1, Leukocyte Function associated Antigen-1; LOX-1, oxidized LDL receptor 1; TSPO, Translocatio 
Protein; VEGF, Vascular Endothelial Growth Factor; MMP, Matrix Metalloprotease; GPVI, Platelet Glycoprotein VI; VCAM-1, 
Vascular Cell Adhesion Molecule-1.
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Figure 2 | Shows 2 cases which exemplify the opportunities and challenges in preclinical imaging using 
multi-pinhole collimators. Image A) shows a contrast enhanced SPECT/CT scan of the thoracic region 
of an ApoE-/- mouse (on 20 weeks high fat diet), imaged with 111In-DANBIRT, which targets leukocytes via 
Leukocyte Function associated Antigen 1 (LFA-1). LFA-1 is expressed in a high-affinity state on leukocytes 
near regions of inflammation, and can therefore be used to visualize inflamed plaque. The image shows 
uptake in plaque regions in the inner curve of the aortic arch and near the aortic leaflets. These common 
sites of plaque formation in this mouse model are visible in the excised, opened Oil Red O stained artery of 
an ApoE-/- mouse on the right B). Image A shows the high resolution which can be achieved with preclinical 
SPECT, considering the mouse aorta is approximately 1 mm in diameter. This case also illustrates some of 
the challenges in preclinical imaging as the small size of the plaque and the presence of few target cells 
require a state of the art imaging system with high resolution and sensitivity. Moreover, the recommended 
injection dose of 20 uL contrast agent per 5 g bodyweight (Exitron nano 12000) can be challenging, as the 
combined injection volume of contrast agent and radiotracer injection can easily exceed the recommended 
injection volume for mice, which can have adverse effects on the animal health and experimental outcome. 
Reduction of the injection volume of the radiopharmaceuticals can be achieved by using smaller tubing 
during radiolabelling. The timing of injection is also important, as blood signal of radiotracers can be high 
after injection, yet the amount of activity reduces with radionuclide half-life. Moreover, many contrast agents 
circulate a limited period in the vasculature. Optimization before an experiment, considering the dose 
and timing of injection, is therefore crucial. In this example, we injected 50 MBq (200 pmol) 111In-DANBIRT 
2 hrs before SPECT imaging, and the contrast agent directly at the start of CT imaging. Scale bar=2 mm. 
(reproduced from (74), no permissions required).
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Images C-F depict an example of a high resolution dual-isotope preclinical SPECT/CT scanning protocol 
applied to diseased human arterial tissue. Examination of the local differences in dual-radiotracer uptake 
with respect to the atherosclerotic pathophysiology was performed on C) a human carotid endarterectomy 
slice of 2 mm thickness, which was incubated for 60 min with 111In-DANBIRT (targeting leukocytes) and 
99mTc-DEMOTATE (targeting activated macrophages) (both 1 nmol, 100 MBq/nmol). DEMOTATE targets 
somatostatin receptor subtype 2, which is expressed on activated macrophages. D) Functional plaque 
morphology was resolved with high resolution μCT (15 min scan, full scan angle, 0.24 mA, 50 kV, 75 ms, 
500 μm reconstructed resolution), where calcifications are denoted by the bright white regions. The asterisk 
(*) marks the sample holder. μCT was co-registered to SPECT (90min scan) reconstructions of E) 111In-DANBIRT 
and F) 99mTc-DEMOTATE. The two radioisotopes can be separated by selecting the correct energy windows 
for the photon peaks of 111In and 99mTc (111In photopeaks 171 and 245 keV, energy windows 158–187 keV 
and 219–267 keV. 99mTc photopeak 140 keV, energy window 125–152 keV). This hybrid functional imaging 
approach can be used to gain greater insights into radiotracer uptake in diseased tissues. Plaque status can 
be assessed via the presence of calcifications, whereas DANBIRT and DEMOTATE ascertain inflammatory 
status by visualizing total inflammation and activated macrophages, respectively. Such scans could lead to a 
better risk stratification of atherosclerotic patients. It is interesting to see the different distribution patterns 
of these inflammation-targeted tracers within the plaque, which indicates that plaque detection alone gives 
only limited information when making a risk stratification of atherosclerotic patients. The timing of imaging 
is important as the radionuclides have different half-lives, and correct separation of the photon peaks 
requires sufficient counts to be acquired. Another challenge is to examine which incubation time allows 
the radiotracers to diffuse into the tissue, while keeping tissue degradation at a minimum (Courtesy H.E.B, 
Erasmus MC).
Perspectives and recommendations
Risk stratification in atherosclerosis: The development of non-invasive imaging techniques 
visualizing atherosclerosis and particularly vulnerable plaque is a major aim in cardiovascular 
imaging (77). The individual and societal impact of such imaging tools can be substantial. They 
could contribute to current risk stratification, which is based on conventional cardiovascular 
risk factors and non-traditional risk factors such as biomarkers and coronary artery calcium 
score. Recent clinical trials focus on the importance of anti-inflammatory strategies for 
treatment of cardiovascular disease (78,79). Biomarkers (e.g. hsCRP, IL-6) are mostly used for 
assessment of inflammation, and might be complemented by non-invasive molecular imaging 
of arterial inflammation in guiding treatment with these new anti-inflammatory drugs. Novel 
tracers therefore could provide extra prognostic value, and aid in further risk-stratification by 
identifying plaques at risk and patients in need of treatment. 
Crossing borders: Diagnostic imaging tools developed for other (non-cardiac) diseases 
such as oncology have been shown to be of significance in atherosclerosis research (80). 
Somatostatin receptor imaging using 68Ga-DOTATATE, developed for diagnosis of neuro-
endocrine tumours, has been validated as a novel marker of atherosclerotic inflammation 
via overexpression of the somatostatin receptor subtype 2 (SST2) on activated macrophages. 
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This has led to better discriminating power of high risk coronary lesions compared to 18F-FDG 
(72,73). Similarly, imaging of macrophages with 68Ga-Pentixafor also originates from oncology 
(70,71). Furthermore, technical challenges in image post-processing in atherosclerosis might 
be improved by developments from other research fields (81,82). Vice versa, research on 
other diseases can benefit from our increased knowledge, as diagnosis of other inflammatory 
diseases such as arthritis can be difficult and hampered by similar challenges encountered in 
atherosclerosis. 
Conclusion
Developments in animal models and imaging systems have facilitated and enhanced the 
opportunities for small radionuclide imaging and will likely continue to do so in the foreseeable 
future. These advances have been essential in preclinical imaging of atherosclerosis, which 
requires high resolution and sensitivity, and has resulted in a large number of novel radiotracers 
being evaluated. This allows ample opportunity for clinical translation, where more insight into 
atherosclerosis, as well as relevant imaging targets, are highly required. 
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Abstract
Background | 111In-DOTA-butylamino-NorBIRT (DANBIRT) is a novel radioligand which binds to 
Leukocyte Function associated-Antigen-1 (LFA-1), expressed on inflammatory cells. This study 
evaluated 111In-DANBIRT for the visualization of atherosclerotic plaque inflammation in mice.
Methods and Results | ApoE-/- mice fed an atherogenic diet up to 20 weeks (n=10), were imaged 
by SPECT/CT 3 hours post injection of 111In-DANBIRT (~200pmol, ~40MBq). Focal spots of 111In-
DANBIRT were visible in the aortic arch of all animals, with an average Target to Background 
Ratio (TBR) of 1.7 ± 0.5. In vivo imaging results were validated by ex vivo SPECT/CT imaging, 
with a TBR up to 11.5 (range: 2.6–11.5). Plaques, identified by Oil Red O lipid-staining on excised 
arteries, co-localised with 111In-DANBIRT uptake as determined by ex vivo autoradiography. 
Subsequent histological processing and in vitro autoradiography confirmed 111In-DANBIRT 
uptake at plaque areas containing CD68 expressing macrophages and LFA-1 expressing 
inflammatory cells. Ex vivo incubation of a human carotid endarterectomy specimen with 111In-
DANBIRT (~950nmol, ~190MBq) for 2 hours showed heterogeneous plaque uptake on SPECT/
CT, after which immunohistochemical analysis demonstrated co-localization of 111In-DANBIRT 
uptake and CD68 and LFA-1 expressing cells.
Conclusions | Our results indicate the potential of radiolabelled DANBIRT as a relevant imaging 
radioligand for non-invasive evaluation of atherosclerotic inflammation.
Abbreviations
LFA-1 Leukocyte Function-associated Antigen-1 
SPECT Single Photon Emission Computed Tomography
CT Computed Tomography




CEA  Carotid Endarterectomy
ROI Region of Interest
TBR Target to Background Ratio
Key words: Atherosclerosis, Inflammation, SPECT, Molecular imaging
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Introduction
Cardiovascular disease remains the major cause of death worldwide1. Most cardiovascular 
events are a consequence of atherosclerosis, in which plaques form due to chronic inflammation 
and lipid accumulation in the vessel wall. Plaque progression can result in plaque rupture and 
subsequent thrombus formation, potentially leading to myocardial infarction or stroke. Timely 
detection of plaque, before rupture, would allow targeted treatment and prevention of a 
potentially life-threatening cardiovascular event. 
Inflammation is a major hallmark of atherosclerosis and a consistent predictor of cardiovascular 
risk (2,3). The recent CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) 
trial showed that reduction of inflammation in patients after myocardial infarction could reduce 
the risk of new adverse cardiovascular events in the future (4). Assessment of the severity of 
inflammation in atherosclerosis using biomarkers is cumbersome however. High sensitive 
C-reactive protein (hsCRP) is a prototypic marker of inflammation and a strong independent 
predictor for future cardiovascular events, yet is influenced by risk factors such as hypertension, 
smoking, and periodontal disease (5). Non-invasive visualization of arterial inflammation may 
complement biomarkers such as hsCRP in guiding treatment with new anti-inflammatory 
drugs.
2-deoxy-2-18F-fluoro-D-glucose Positron Emission Tomography (18F-FDG PET) imaging is an 
established method to non-invasively detect and quantify inflammation within atherosclerotic 
plaques (6-8). FDG is a glucose analogue, which accumulates in metabolically active cells, 
including plaque-associated macrophages. However, due to the high metabolic activity 
of myocardial cells, 18F-FDG uptake by the myocardium might hinder detection of coronary 
atherosclerotic plaques. Furthermore, a necessary fasting period before imaging and non-
specific uptake limit the applicability of 18F-FDG (9,10). These limitations warrant the search for 
additional radiotracers which might complement 18F-FDG.
Development of atherosclerosis is initiated by adhesion of monocytes as well as T lymphocytes 
to the arterial endothelial surface, followed by their migration into the subendothelial space 
(11). Leukocyte Function-associated Antigen-1 (LFA-1), consisting of CD11a and CD18 subunits, 
is an integrin cell-surface receptor expressed on leukocytes. LFA-1 binds to endothelial 
cells via interaction with Intercellular Adhesion Molecule 1 (ICAM-1), and is involved in 
transmigration of inflammatory cells to sites of inflammation (12). LFA-1 was first identified as 
one of several adhesion molecules playing a role in leukocyte trafficking, antigen presentation 
and cell activation. Immunohistochemical studies on animal models of atherosclerosis 
have demonstrated the presence of LFA-1 positive cells in atherosclerotic lesions (13,14). 
Therefore, LFA-1 may be a promising imaging target for atherosclerotic plaque detection. 
Recently, an allosteric inhibitor of LFA-1 (15) was chemically adapted for nuclear diagnostic 
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and therapeutic purposes ((R)-1-(4-aminobutyl)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-
5-methylimidazolidine-2,4-dione; butylamino-NorBIRT) (16). Butyl-amino-NorBIRT can be 
labelled with various radionuclides for Single Photon Emission Computed Tomography (SPECT) 
and PET imaging via a chelator (e.g. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA)), depicted in Figure 1. Indium-111-DOTA-butylamino-NorBIRT (111In-DANBIRT) is used 
for SPECT imaging and has been shown to specifically bind LFA-1 on cultured human leukemic 
and mouse lymphoma cells (16,17). 
The aim of this study was to examine the feasibility of plaque detection using 111In-DANBIRT. 
To this end, we studied in vivo uptake in ApoE-/- mice via SPECT/Computed Tomography (CT) 
scanning, and established its binding to human plaque material. 
Figure 1 | Chemical structure of *R-DANBIRT. 1-(4-aminobutyl)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-
5-methylimidazolidine-2,4-dione-DOTA. R, radiometal.
Materials and Methods
Animals and experimental setup
Female ApoE -/- mice on a C57BL/6J background (n=10) were purchased from Charles Rivers 
(Calco, Italy) at 6 weeks of age and were fed a high fat diet (0.3% cholesterol, Altromin 
Spezialfutter GmbH & Co. KG, Lage, Germany) ad libitum from 8 weeks of age onwards up 
to a maximum of 20 weeks. After SPECT/CT imaging, mice were sacrificed by an overdose of 
inhalation anaesthesia (isoflurane). All animal experiments were approved by the institutional 
animal studies committee and were in accordance with Dutch animal ethical legislation and 
the European Union Directive.
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Radiolabelling
111In-DANBIRT (MW=886.5 g/mole) (provided by J.P. Norenberg) was radiolabelled with 111In 
(Covidien, Petten, The Netherlands) with a specific activity of 200 MBq/nmol, as previously 
described (18). Radiochemical purity (>90%) and incorporation yield (>99%) were assessed 
using high-pressure liquid chromatography and instant thin-layer chromatography on silica 
gel. Quenchers (3.5 mM ascorbic acid, 3.5 mM gentisic acid, 10 mM methionine) were added to 
prevent radiolysis of the tracer (19).
In vivo imaging
Mice were injected intravenously in the tail vein with ~40 MBq/200 pmol 111In-DANBIRT in 0.1% 
Bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (injection volume of 150 µL) 
(n=10). They were anesthetized (1.5–2% isoflurane) 2.5 hours post injection, after which they 
were injected with 100 µL CT-contrast agent (eXIA160, Binito Biomedical Inc, Ottawa, ON, 
Canada; or Exitron nano 12000 ,Milteny Biotec, Bergisch-Gladach, Germany). Immediately after 
contrast injection, a CT scan was performed (17 min, 615 mA, 55 KeV) followed by a SPECT 
scan (static scan, 1 hr, 2.0 mm pinhole collimator, 17 positions) on a hybrid SPECT/CT scanner 
(VECTor, MILabs, Utrecht, Netherlands) with a reported spatial resolution of 0.85 mm (20). SPECT 
images were reconstructed using photopeak windows of 214–262 and 152–185 KeV, with a 
background window on either side of the photopeak with a width of 2.5% of the corresponding 
photopeak, and a pixel-based ordered subset expectation maximization method (4 subsets 
and 30 iterations), a voxel size of 0.8 mm3, and corrected for attenuation using the CT data. 
A post-reconstruction 3-dimensional Gaussian filter was applied (0.8 mm full width at half 
maximum). A blocking study was performed by co-injection with a100x or 850x excess of 
unlabelled DANBIRT in 2 mice. 
Ex vivo studies
After imaging, mice were euthanized and vasculature was flushed with PBS via the left 
ventricle, followed by excision of the aorta and carotid arteries. The arteries were cleaned 
from visceral fat and connective tissue and stained for lipids (Oil red O (ORO) according to 
standard protocol) to confirm plaque presence. After staining, the arteries were scanned ex 
vivo (CT: 5 min, 615 mA, 55 KeV; SPECT: static scan, 30 min, 2.0 mm pinhole collimator) on a 
SPECT/CT scanner (VECTor, MILabs, Utrecht, Netherlands). SPECT images were reconstructed 
as described above. Subsequently, arteries were used for ex vivo autoradiography (n=4) or 
embedded in tissue-tec and stored at -80° C for histological analysis (n=6). To determine the 
biodistribution of 111In-DANBIRT in ApoE-/- mice, selected organs were collected, weighed and 
measured for radioactivity in a gamma-counter (1480 Wizard, Gamma counter, Perkin Elmer). 
Radioactivity measured in the various tissues was expressed as percentage of injected dose 
per gram (%ID/g). 111In-DANBIRT showed a biodistribution pattern according to expectation, 
with limited retention in major organs 24 hours post injection (Online Resource 1). After ~3 
weeks, arteries used for ex vivo autoradiography were placed on a phosphor screen overnight 
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and read using a phosphor imager (Cyclone; Perkin Elmer). Plaque signal was quantified as 
digital light units/mm2 (DLU/mm2) using Optiquant software (Perkin Elmer), and compared to 
non-diseased arterial signal in the same sample to calculate a Target to Background Ratio (TBR).
Ex vivo carotid endarterectomy study
To explore binding to human atherosclerotic plaques, we incubated a human carotid 
endarterectomy (CEA, acquired with informed consent and approved by the medical ethics 
committee) sample with 111In-DANBIRT (~950 pmol, ~190 MBq) in 0.1% BSA in PBS for 2 hours. 
After incubation the specimen was washed in PBS and subsequently scanned on the SPECT/
CT scanner (CT: 5 min, 615 mA, 55 keV; SPECT: static scan, 30 min, 2.0 mm pinhole collimator). 
SPECT images were reconstructed as described above. Hereafter, the specimen was cut in 
transverse slices of 1 mm. Even slices were used for autoradiography, odd slice for histological 
evaluation. Histology was visually matched with transverse views of the SPECT/CT scan, to 
correlate 111In-DANBIRT uptake with locations of cells expressing LFA-1 and CD68. 
Immunohistochemistry and In vitro autoradiography
Mouse aortic arch cryosections and human CEA cryosections (both 5 µm) were immuno-
histochemically stained with anti-CD68, a pan-macrophage marker (human: 1:100, Abcam, 
ab955; mouse: 1:100 Biorad, MCA1957), and anti-LFA-1 (human: 1:100 Biorad, MCA1848; mouse: 
1:1, Pont et al., 1986 (21)) to assess co-localization of LFA-1 and CD68 (macrophage)-positive 
cells. In vitro autoradiography was performed on mouse cryosections (10 µm) of aortic arch 
adjacent to slides used for immunohistochemistry, by incubating slides for 1 hr with 80 µL 10-9 M 
111In-DANBIRT. Serially sectioned human CEA cryosections (10 µm) were incubated for 1 hr with 
80 µL 10-9 M 111In-DANBIRT with or without excess (10-6 M) unlabelled DANBIRT to determine 
non-specific binding. Slides were exposed to phosphor screens for 1 week and read using a 
phosphor imager (Cyclone; Perkin Elmer). The autoradiograms of human CEA cryosections 
were analysed by drawing fixed regions of interests (ROIs) around the sections using Optiquant 
software (Perkin Elmer). Signal was quantified as DLU/mm2, after which blocked and unblocked 
sections were compared using a student’s t-test. 
Quantification
SPECT data was analysed with Vivoquant (Invicro) by quantification of manually drawn regions 
of interests (ROIs) based on contrast-enhanced CT. On in vivo scans, ROIs were drawn in the 
aortic arch, vena cava inferior and jugular vein. ROIs on ex vivo scans were drawn in the aortic 
arch and non-diseased artery in the descending aorta or common carotid arteries. TBRs were 
calculated, and expressed as mean ± standard deviation. 
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Results
In vivo mouse plaque imaging
In vivo SPECT/CT imaging 3 hours after intravenous injection of 111In-DANBIRT showed distinct 
focal spots of radioactivity, corresponding to common sites of plaque formation in the aortic 
arch of all animals (Figure 2 and Online Resource 4), with an average TBR of 1.7 ± 0.5. Uptake 
of 111In-DANBIRT at plaque locations in the carotid bifurcations was not above background. 
Myocardial uptake was not above background in any of the animals. Co-injection of excess 
unlabelled DANBIRT reduced uptake of 111In-DANBIRT in plaque areas of the aortic arch to 
background levels (Online Resource 2).
Figure 2 | In vivo uptake of 111In-DANBIRT in atherosclerotic mice. In vivo contrast enhanced Computed 
Tomography (CT), Single Photon Emission Computed Tomography (SPECT), and overlay images of ApoE-/- 
mouse thorax in coronal, sagittal, and transverse view. Scans were made 3 hrs post injection. Exitron nano 
12000 was used as contrast agent. 1=aortic arch; 2=right common carotid artery; 3=left common carotid 
artery; 4=left subclavian artery. V=ventral, D=dorsal. Arrowheads indicate radioactive hot spots (111In-
DANBIRT uptake) in the aortic arch. 
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Ex vivo validation
After in vivo imaging, arteries were excised and scanned ex vivo. Focal uptake of 111In-DANBIRT 
in the aortic plaques was evident (Figure 3A), with a TBR up to 11.5 (range: 2.6–11.5). To co-
localize uptake to plaque locations, we performed ex vivo autoradiography and a lipid staining 
(ORO) on the excised arteries. The ex vivo autoradiography showed high 111In-DANBIRT uptake 
in regions in the aortic arch, arterial branch points, descending aorta, and carotid bifurcations, 
corresponding to plaque locations as indicated by lipid staining (Figure 3A) with an average TBR 
of 19.0 ± 7.9. In vitro autoradiography and immunohistochemistry of mouse aorta containing 
plaque demonstrated 111In-DANBIRT binding to plaque areas containing LFA-1-expressing 
inflammatory cells and CD68-positive macrophages (Figure 3B). Binding of 111In-DANBIRT to 
human plaque cryosections could be blocked by addition of an excess of unlabelled DANBIRT 
(Online Resource 3).
Figure 3 | Ex vivo validation of 111In-DANBIRT imaging of LFA-1. Frontal view of ex vivo CT, SPECT, and 
overlay images of an excised artery of an ApoE-/- mouse, autoradiography (ARG) and bright field photo of Oil 
Red O (ORO) stained, opened artery excised from another ApoE-/- mouse, both injected with 111In-DANBIRT. 
1=aortic arch; 2=right common carotid artery; 3= left common carotid artery. Asterisks (*) indicate locations 
of needles used to pin down the artery. Scale bar=2 mm (panel A). In vitro autoradiography of 10 µm 
cryosection of mouse aortic arch. Adjacent 5 µm cryosections immunohistochemically stained for LFA-1 and 
CD68 expression. Scale bar=100 µm (panel B).
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Human plaque imaging
Incubation of a human CEA sample with 111In-DANBIRT resulted in heterogeneous uptake of 
111In-DANBIRT seen as hot spots throughout the plaque in SPECT/CT scans (Figure 4 A, B, and 
Online Resource 5). Subsequent histological analysis of adjacent cryosections demonstrated 
co-localization of the hotspots of 111In-DANBIRT uptake with LFA-1-expressing inflammatory 
cells and CD68-positive macrophages (Figure 4 C, D, E, F). 
Figure 4 | Ex vivo 111In-DANBIRT imaging of LFA-1 in a human atherosclerotic plaque. Bright field photo 
of a Carotid Endarterectomy specimen. Yellow line indicates location of transverse view of SPECT/CT scan 
in C, autoradiography of 1 mm thick transverse slide in D, and adjacent histologic sections in E and F. Scale 
bar=10mm A). SPECT/CT imaging show heterogeneous uptake of 111In-DANBIRT. Calcified regions of the 
plaque are visible in bright white in the CT views. Pins used as landmarks are indicated by asterisks (*). 
Coronal B), and transverse views C) of SPECT/CT scan. Ex vivo autoradiography image D). LFA-1 expression is 
visible in a slide adjacent to D, co-localizing with areas of high 111In-DANBIRT uptake. Inset shows overview 
of the histological section, asterisk shows location of zoomed area. Scale bar=100 µm E). CD68 expressing 
macrophages are present in an adjacent cryosection. Inset shows overview of the histological section, 
asterisk shows location of zoomed area. Scale bar=100 µm F). L=Lumen.
Discussion
In this study we show the feasibility of in vivo plaque detection using 111In-DANBIRT SPECT/
CT imaging of LFA-1. We demonstrated distinct focal uptake in the aortic arch of all animals 
3 hours after intravenous injection of 111In-DANBIRT, despite the small dimensions of murine 
arteries and plaques. This uptake was related to the presence of lipid rich plaques with 
inflammatory cells shown by ORO staining and immunohistochemistry. Moreover, we showed 
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uptake of 111In-DANBIRT in an excised human carotid plaque. In addition, presence of LFA-1 
positive cells in atherosclerotic plaque was confirmed by immunohistochemistry. The finding 
that 111In-DANBIRT can detect plaques in murine aortas (vessel diameter <1 mm) point towards 
its possible applicability in human coronary arteries which have a common diameter of around 
3 mm (22).
Various non-invasive imaging techniques are explored for the early detection of atherosclerosis 
and risk stratification of patients with cardiovascular disease, using various target-ligand 
combinations that are associated with atherosclerosis. The clinically most frequently explored 
technique is 18F-FDG PET, which has limits in regards to its specificity and myocardial uptake. 
DANBIRT, in this study labelled with 111In, solely binds to inflammatory cells and was not taken 
up by the myocardium in our atherosclerotic mouse model. As such, DANBIRT might surpass 
a limitation of 18F-FDG. Moreover, DANBIRT might provide information on different stages of 
plaque development as all leukocytes express LFA-1. Furthermore, DANBIRT can be labelled 
with 68Ga, which makes it suitable for PET imaging and enhances its clinical applicability.
111In-DANBIRT signal was not visible by in vivo nor ex vivo SPECT/CT imaging of the plaque 
in the carotid artery bifurcations, whereas the more sensitive ex vivo autoradiography did 
demonstrate uptake. This could be due to a smaller plaque size and/or a lower number, or 
a more diffuse distribution of inflammatory cells, resulting in a signal below the detection 
threshold of our SPECT system.
111In-DANBIRT exhibits specific uptake in plaques in atherosclerotic mice. Uptake of 111In-
DANBIRT occurs in plaque areas that contain LFA-1 expressing leukocytes and CD68 
positive macrophages, indicating specific targeting of LFA-1 positive cells. We conclude 
that radiolabelled DANBIRT shows potential as a relevant nuclear imaging tracer to detect 
atherosclerotic inflammation. Upon confirmation of these findings in a patient population, this 
imaging tool may be used to improve risk assessment of cardiovascular disease by visualizing 
inflammation and for individualizing specific anti-inflammatory drug therapy.
New knowledge gained
The novel LFA-1 targeting radioligand DANBIRT detects inflammation in vivo in atherosclerotic 
plaques in an ApoE-/- mouse model. DANBIRT uptake correlates to the presence of CD68 
expressing macrophages and LFA-1 expressing inflammatory cells in the atherosclerotic plaque. 
In addition, ex vivo uptake of DANBIRT in a human carotid plaque correlates to the presence 
of CD68 expressing macrophages and LFA-1 expressing inflammatory cells, suggesting the 
potential of DANBIRT for non-invasive imaging of atherosclerotic plaque inflammation.
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Background | Imaging Somatostatin Subtype Receptor 2 (SST2) expressing macrophages by 
[DOTA,Tyr3]-octreotate (DOTATATE) has proven successful for plaque detection. DOTA-JR11 
is a SST2 targeting ligand with a five times higher tumour uptake than DOTATATE, and holds 
promise to improve plaque imaging. The aim of this study was to evaluate the potential of 
DOTA-JR11 for plaque detection. 
Methods and Results | Atherosclerotic ApoE-/- mice (n=22) fed an atherogenic diet were imaged 
by SPECT/CT two hours post injection of [111In]In-DOTA-JR11 (~200pmol, ~50MBq). In vivo 
plaque uptake of [111In]In-DOTA-JR11 was visible in all mice, with a Target-to-Background-Ratio 
(TBR) of 2.23 ± 0.35. Post mortem scans after thymectomy and ex vivo scans of the arteries after 
excision of the arteries confirmed plaque uptake of the radioligand with TBRs of 2.46 ± 0.52. 
and 3.43 ± 1.45 respectively. Oil red O lipid-staining and ex vivo autoradiography of excised 
arteries showed [111In]In-DOTA-JR11 uptake at plaque locations. Histological processing showed 
CD68 (macrophages) and SST2 expressing cells in plaques. SPECT/CT, in vitro autoradiography 
and immunohistochemistry performed on slices of a human carotid endarterectomy sample 
showed [111In]In-DOTA-JR11 uptake at plaque locations containing CD68 and SST2 expressing 
cells. 
Conclusions | The results of this study indicate DOTA-JR11 as a promising ligand for visualization 
of atherosclerotic plaque inflammation. 
Abbreviations
SST2 Somatostatin subtype receptor 2
SPECT Single photon emission tomography
CT Computed tomography
ORO Oil red O
CEA Carotid Endarterectomy
TBR Target to background ratio
Key words: SPECT, atherosclerosis, inflammation, molecular imaging
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Introduction
Cardiovascular disease is the leading cause of death worldwide (1). Most cardiovascular 
events are caused by atherosclerosis, in which plaques form over time due to continuous 
inflammation and lipid deposition in the arterial wall. Current imaging techniques focus on 
plaque morphology or measures such as calcium score, which are used for cardiovascular risk 
assessment to improve clinical risk scores (2). Inflammation is a crucial factor in atherosclerotic 
plaque and plays a crucial role in plaque initiation, progression, and destabilization (3,4). 
Imaging plaque inflammation may complement traditional imaging methods, providing a 
better risk stratification of patients at risk of future cardiovascular events.
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) has proven a reliable non-invasive imaging method 
not only to detect, but even to quantify the degree of inflammation in plaques (5-7). 18F-FDG, 
therefore, provides a valuable tool to assess and monitor disease burden (8). However, 
background uptake in normal tissue and high uptake of 18F-FDG in the myocardium severely 
hinders detection of coronary plaques (9,10), and warrants the search for novel radioligands.
Somatostatin Subtype Receptor 2 (SST2) is highly expressed on activated macrophages (11,12). 
As macrophages are the main inflammatory cell type in atherosclerotic plaque, SST2 has been 
proposed as a relevant imaging target for inflammation-based plaque detection. A number of 
studies have reported on the use of SST2 for inflammation-based imaging of atherosclerosis 
(13-19). Moreover, Tarkin et al. recently prospectively validated [68Ga]Ga-[DOTA, Tyr3]-octreotate 
(DOTATATE) as a marker for plaque inflammation (20) in a clinical study. They demonstrated 
the feasibility to detect both carotid and coronary plaques with [68Ga]Ga-DOTATATE. Moreover, 
[68Ga]Ga-DOTATATE could better discriminate between high-risk and low-risk lesions compared 
to [18F]FDG.
Various radioligands, based on SST2 agonists, for SST2-targeted imaging and therapy have been 
developed and used over the past 20 years for detection and treatment of SST2-expressing 
tumors (21). More recently, a new generation of radioligands based on SST2 antagonists has 
been developed and described, showing more favourable pharmacokinetics and higher 
tumour uptake than agonists like DOTATATE. Of these, the compound JR11 (Cpac[D-Cys-
Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]-D-Tyr-NH2) performed best in preclinical and clinical 
studies as an imaging as well as a therapeutic agent (21-24). Based on the reported favourable 
biodistribution and targeting efficiency of DOTA-JR11, we studied the potential of DOTA-JR11 
in inflammation imaging for atherosclerotic plaque detection as it could yield higher TBRs 
than agonistic radioligands. We therefore used [111In]In-DOTA-JR11 Single Photon Emission 
Computed Tomography/Computed Tomography (SPECT/CT) to image plaques in vivo in an 
atherosclerotic mouse model, and assessed target binding in human plaque material. 
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Animals and experimental setup
Atherosclerotic female ApoE-/- mice on a C67BL/6J background (n=22) were purchased from 
Charles Rivers (Calco, Italy) at 6 weeks of age, and were fed a high fat diet (0.3% cholesterol, 
Altromin Spezialfutter GmbH & Co. KG, Lage, Germany) ad libitum from an age of 8 weeks up to 
20 weeks. All animal experiments were approved by the institutional animal studies committee 
and were in accordance with Dutch animal ethical legislation and the European Union Directive.
Radiolabelling
[111In]In-DOTA-JR11 (MW=1690 g/mol) (kindly provided by Dr. Helmut Maecke) was radiolabelled 
with [111In]InCl3 (Covidien, Petten, The Netherlands) with a specific activity of 200 MBq/nmol as 
described previously (25). Radiochemical purity (>95%) and incorporation yield (>99%) were 
evaluated with high-pressure liquid chromatography and instant thin-layer chromatography 
on silica gel. Quenchers (3.5 mM gentisic acid, 3.5 mM ascorbic acid, 7% ethanol) were added 
to prevent radiolysis as described previously (26).
In vivo imaging and validation 
Mice (n=22) were injected with 50 MBq/200 pmol [111In]In-DOTA-JR11 in Phosphate Buffered 
Saline (PBS) with 0.1% Bovine Serum Albumin (BSA), with a total injection volume of 150 µL. 
Four mice were co-injected with a 100x excess of unlabelled DOTA-JR11 to test the specificity 
of the radioligand. Mice were anesthetized with 1.5% isofluorane two hours post injection, 
after which they were injected with 50 µL CT-contrast agent (Exitron Nano 12000, Milteny 
Biotec, Bergisch-Gladbach, Germany). Immediately after contrast agent injection, mice were 
transferred to a VECTor5/CT scanner (MILabs B.V. Utrecht, The Netherlands) on which a CT scan 
was made followed by a SPECT scan. The time between radioligand injection and imaging 
was based on pilot experiments (data not shown). The CT scan was made with the following 
settings: full scan angle; accurate scan mode; 50 kV tube voltage; 0.24 mA tube current; 3.5 
minute scan time. CT scans were reconstructed at a resolution of 80 µm. SPECT was performed 
with the M3.0 pinhole collimator (resolution <1.3 mm, sensitivity >30000 cps/MBq). Data were 
acquired in list-mode using the following acquisition parameters: 1 hour scan; 15 positions; 
spiral scan mode; fine step mode. Scans were reconstructed with energy windows incorporating 
a width of 20% of the In-111 photo peaks of 171 and 245 keV with background windows of 
2.5% on either side of the photo peak windows, and scatter correction was applied according 
to (27). Reconstructions were performed with a SROSEM (Similarity Regulated Ordered Subset 
Expectation Maximization (28) algorithm with 9 iterations, 128 subsets, with a voxel size of 
0.4 mm and a post reconstruction 3-dimensional Gaussian filter was applied (1 mm full width 
at half maximum).
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After in vivo imaging, mice were euthanized with an overdose of isoflurane, after which the 
vasculature was flushed with PBS via the left ventricle, and thymectomy was performed. In this 
state, the thorax of the euthanized mice was scanned ‘in situ’ to circumvent signal interference 
from thymic uptake of [111In]In-DOTA-JR11 with signal from plaque uptake. CT and SPECT 
settings for in situ imaging were the same as for in vivo imaging, except for a shorter SPECT 
scan duration of 30 minutes.
The arteries were removed after in situ imaging, and cleaned of remaining connective tissue. 
They were then stained for lipids (Oil Red O (ORO) according to standard protocol) to confirm 
plaque presence, and scanned ex vivo with SPECT/CT. The scan settings for ex vivo imaging 
were the same as in situ settings except for four SPECT positions due to a smaller field of 
view. Subsequently, the arteries were cut open and used for ex vivo autoradiography (n=4) or 
embedded in Tissue-Tek O.C.T. compound (Sakura Finetek Europe B.V., Alphen aan den Rijn, 
The Netherlands) and stored at -80° C for histological analysis (n=14). After ~2weeks, arteries 
used for ex vivo autoradiography were placed on a phosphor screen overnight and read using 
a phosphor imager (Cyclone, Perkin Elmer).
Ex vivo carotid endarterectomy study
To investigate binding of [111In]In-DOTA-JR11 to and its potential for imaging of human plaque 
tissue, we performed an ex vivo study with human carotid endarterectomy (CEA) tissue slices. 
For this purpose we sliced a CEA sample (acquired with informed consent and approved by the 
medical ethics committee of the Erasmus MC, MEC 2008-147) into 2 mm slices. Even-numbered 
slices were embedded in O.C.T. compound and stored at -80° C for later in vitro binding assays 
and histological evaluation. Odd-numbered slices were incubated with 200 MBq/1 nmol 
[111In]In-DOTA-JR11 in 20 mL PBS with 0.1% BSA for one hour. After incubation, the slices 
were washed in PBS with 0.1% BSA until no residual radioactivity remained in the washing 
medium as measured by a dose calibrator (Dose calibrator VDC-405, Comecer Netherlands, 
Joure, The Netherlands). The slices were subsequently placed on a holder, and imaged with 
the VECTor5/CT. CT and SPECT settings were the same as for the in vivo mouse scan, except a 
mouse 1.6 pinhole collimator (resolution <1.6 mm, sensitivity >1500 cps/MBq) was used with 
38 scan positions, and the scans were reconstructed with a Gaussian filter of 0.5 mm full width 
at half maximum.
Immunohistochemistry and in vitro binding assays 
Embedded mouse arteries and CEA slices were sectioned into 5 µm sections, which were 
immunohistochemically stained for CD68 (Mouse: 1:100, Biorad, MCA1848; human: 1:100, 
Abcam, ab955) and SST2 (1:100, Abcam, clone UMB-1) to assess target presence and presence 
of macrophages. In short, sections were fixed in cold acetone for 5 minutes, endogenous 
peroxidase was blocked with 0.3% H2O2, and non-specific binding was blocked with 1% BSA 
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for mouse CD68 staining and 2% normal goat serum for SST and human CD68 staining. The 
primary antibody was omitted from the protocol in negative controls.
10 µm sections, adjacent to the 5 µm sections used for immunohistochemistry, were cut from 
the embedded CEA slices to assess radioligand uptake via an in vitro competition binding 
assay (autoradiography). Sections were incubated for 1 hour with 10-9 M [111In]In-DOTA-JR11 
with or without an excess of 10-6 M unlabelled DOTA-JR11 to asses specific binding. Slides were 
exposed to phosphor screens overnight and read with a phosphor imager (Cyclone, Perkin 
Elmer). Haematoxylin-eosin staining according to standard protocol was performed on the 
sections afterwards.
Quantification and statistics
SPECT/CT data were analysed with Vivoquant (Invicro) by quantification of the activity within 
manually drawn regions of interests (ROIs) based on contrast-enhanced CT images. In vivo 
ROIs were drawn for the aortic arch and the brachiocephalic artery, whereas the vena cava 
inferior and jugular vein were used as background regions. In situ ROIs were the aortic arch 
and brachiocephalic artery, and the heart ventricles were taken as background tissue. ROIs on 
ex vivo images were also the aortic arch and brachiocephalic artery for plaque areas, and the 
relatively healthy descending thoracic aorta as background. Target to background ratios (TBRs) 
were calculated and expressed as mean ± standard deviation. 
In vitro autoradiography analysis was performed by drawing ROIs around tissue sections 
in Optiquant (Perkin Elmer), quantifying the signal as Digital Light Units (DLU)/mm2 and 
comparing non-blocked to blocked tissue sections. 
The Shapiro-Wilk test was used to test data for normality. The student’s t-test was used to 




In vivo SPECT/CT imaging 2 hours after intravenous injection of [111In]In-DOTA-JR11 showed 
focal uptake at locations of plaque formation in the vasculature of all animals (Figure 1A-D), 
with an average TBR of 2.23 ± 0.35. Thymic uptake (average TBR of 2.28 ± 0.51) of [111In]In-
DOTA-JR11 masked plaque signal and therefore complicated visualization and quantification. 
Therefore, ‘in situ’ scans were made in post-mortem thymectomized animals. In situ SPECT/CT 
imaging confirmed plaque uptake of [111In]In-DOTA-JR11 as seen in in vivo images (Figure 1E-
H), with a TBR of 2.46 ± 0.52. Blocking studies with an 100x excess of DOTA-JR11 significantly 
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reduced the arterial signal (TBR in vivo blocked: 1.47 ± 0.36; TBR in situ blocked: 1.36 ± 0.15, 
p=0.05, see Figure 1I and Online Resource 1) Likewise, blocking significantly reduced uptake in 
the thymus (TBR 1.32 ± 0.43, p=0.05). 
Presence of plaque in excised arteries was confirmed by ORO staining of excised arteries. Ex 
vivo SPECT/CT imaging of the mouse arteries showed uptake of [111In]In-DOTA-JR11 at plaque 
locations in the aortic arch and brachiocephalic artery with a TBR of 3.43 ± 1.45 (Figure 1J). Ex 
vivo autoradiography and ORO staining of excised, cut open arteries confirmed uptake of [111In]
In-DOTA-JR11 in plaque (Figure 2A and B). Immunohistochemistry of the arteries confirmed 
presence of SST2 and CD68 expressing cells in plaque (Figure 2C-F).
Figure 2 | A) Excised, cut open and Oil red O stained arteries of a mouse injected with 200 pmol [111In]In-DOTA-
JR11. Scale bar indicates 2 mm. B) Matching high resolution ex vivo autoradiogram to the arteries shown in 
(A), showing [111In]In-DOTA-JR11 uptake at plaque locations. C) and D) show immunohistochemistry for CD68 
(macrophages) and Somatostatin Subtype Receptor 2 (SST2) expressing cells in mouse plaque, respectively. 
Scale bar indicates 100 µm. E) and F) show the overview of the histological sections shown in (C) and (D); the 
asterisk marks the location of the zoomed area in (C) and (D). Scale bar indicates 2.5 mm.
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Human plaque imaging
Two millimetre thick slices of a human carotid endarterectomy sample incubated with [111In]
In-DOTA-JR11 showed focal hotspots of radioligand uptake detectable by SPECT, reflecting the 
presence of SST2 as determined by immunohistochemistry (Figure 3). Noticeably, no radioligand 
uptake or SST2 expression was visible in areas of macrocalcifications visible in CT. In vitro 
autoradiography performed on 10 µm sections of adjacent 2 mm slices showed specific binding 
of [111In]In-DOTA-JR11 when compared to adjacent sections incubated with a 1000x excess of 
unlabelled DOTA-JR11 (non blocked=35*106 ± 90*105, blocked=25*106 ± 63*105 DLU/mm2, 
p=0.005, see Online Resource 2 and Figure 3). Moreover, radioligand uptake visualized on in 
vitro autoradiography co-localized with CD68 and SST2 expression on adjacent sections, and 
signal as seen on the SPECT/CT images of the adjacent 2 mm slices (Figure 3B-E).
Figure 3 | [111In]In-DOTA-JR11 uptake in human carotid endarterectomy (CEA) tissue after incubation with 
[111In]In-DOTA-JR11. A) Transverse SPECT/CT image of a two mm slice of a CEA sample. Calcifications are 
visible in CT in white, the asterisk indicates the holder used to keep the two mm slice in place. B) and C) In vitro 
autoradiography of adjacent 10 µm sections made of an adjacent two mm slice of the same CEA sample seen 
in (A). The section in B) was incubated with 10-9 M [111In]In-DOTA-JR11, the section in C) was incubated with 
10-9 M [111In]In-DOTA-JR11 plus a blocking dose of 10-6 M unlabelled DOTA-JR11. The inset shows the boxed 
region at higher magnification, the red arrows indicate sectioning artefacts (tissue folds). D) SST2 and E) CD68 
immunohistochemistry on 5 µm sections adjacent to B) and C), with matching insets. Scale bar indicates 
two mm.
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We have demonstrated the feasibility of imaging atherosclerotic plaques by targeting SST2 
with DOTA-JR11, by visualizing plaque with In-111 labelled DOTA-JR11 in a mouse model of 
atherosclerosis and in human plaque tissue. We showed that radioligand uptake is located in 
plaque regions in the mouse vasculature as evidenced by in vivo and in situ SPECT/CT imaging, 
autoradiography, and ORO staining. [111In]In-DOTA-JR11 uptake in human plaque tissue co-
localizes with SST2 and CD68 expressing cells, whereas blocking studies show target-specific 
uptake in vivo and in situ in mouse plaque, and in vitro in human tissue. 
High thymic uptake of [111In]In-DOTA-JR11, visible in the in vivo SPECT images and in line with 
reported SST2 expression in mice in this tissue (29), is problematic when visualizing plaque 
in the used atherosclerotic model. Nevertheless, we demonstrated that the in vivo signal 
visible next to the thymus did originate from plaque, by comparing the intensity and the 
localization of plaque signal in the in vivo, in situ, and ex vivo SPECT scans, as well as the ex vivo 
autoradiography. Thymic uptake is not expected to interfere with human plaque imaging as 
thymic activity wanes during adolescence, and little SST2–ligand binding has been found in 
dedicated studies (30). Ex vivo imaging of a human CEA sample showed that SPECT imaging 
using [111In]In-DOTA-JR11 is feasible in human plaque tissue and that radioligand uptake co-
localizes to regions of inflammation as evidenced by CD68 and SST2 immunohistochemistry. 
These results indicate that DOTA-JR11 has potential for imaging of inflammation in human 
plaques.
Oncological studies reported a five times higher uptake of DOTA-JR11 over DOTATATE in SST2 
positive tumours (21-23). It is hypothesized that antagonistic ligands such as DOTA-JR11 have 
more binding sites on the receptor than agonistic ligands such as DOTATATE (31). Although the 
exact mechanism for this difference in uptake remains to be elucidated, the growing amount 
of studies using SST2-mediated imaging in atherosclerosis (13-19) indicate DOTA-JR11 as an 
interesting candidate for further studies. 
DOTATATE and DOTA-JR11 have not been compared for the detection of atherosclerotic 
plaque. Two preclinical studies have tested [68Ga]Ga-DOTATATE for plaque imaging in mouse 
models, however. Although it is difficult to compare studies using different animal models and 
different imaging systems, the results found in (14,15) indicate that [68Ga]Ga-DOTATATE has a 
lower TBR compared to [111In]In-DOTA-JR11 our study. Rinne et al. found an aorta to blood ratio 
of 0.67 ± 0.04 using [68Ga]Ga-DOTATATE in vivo in IFG-II/LDLR-/-ApoB100/100 mice (15), indicating 
low radioligand uptake in plaque. However, they also reported a high plaque to wall ratio of 
2.1 ± 0.5 for [68Ga]Ga-DOTATATE in autoradiographic studies. Li et al. found a similar plaque to 
non plaque ratio of ~1.8 after autoradiographic analysis of ApoE-/- arteries incubated with [68Ga]
Ga-DOTATATE (14). We found an in vivo TBR of 2.23 ± 0.35 and an in situ TBR of 2.46 ± 0.52, and in 
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 67
67A Road to Improved Diagnostics – Imaging Inflammatory Cells in Atherosclerosis | 
4
the autoradiogram of the mouse arteries we found a TBR of 3.43 ± 1.45. Taken together, these 
studies warrant further investigations into the added value of DOTA-JR11 over DOTATATE in 
atherosclerotic patients.
If a five times higher uptake of DOTA-JR11, as was found in oncological studies, would be found 
in atherosclerosis as well, DOTA-JR11 could offer possibilities for visualization of less inflamed 
plaques or plaques with lower SST2 expression. Moreover, the DOTA chelator of JR11 allows 
labelling with different radionuclides including Ga-68, making DOTA-JR11 attractive for PET 
imaging. Although different radiometals result in differences in binding affinity of DOTA-JR11 
(32), the attractive pharmacokinetics of DOTA-JR11 are conserved when labelled with Ga-68 
(24). 
Because inflammation in different plaque regions can have a substantial effect on the rupture 
risk of atherosclerotic plaques, future studies should investigate whether DOTA-JR11 uptake 
can be correlated to different plaque phenotypes. A better interpretation of radioligand uptake 
related to plaque phenotype could be a major step in patient risk stratification.
 
Conclusion
Our results indicate DOTA-JR11 as a promising ligand for atherosclerosis imaging based on 
our promising in vivo results and ex vivo validation studies. DOTA-JR11 could be a valuable 
improvement in imaging of inflammation in atherosclerotic disease. 
New Knowledge Gained
The SST2 targeting radioligand [
111In]In-DOTA-JR11 can be used to detect plaques in a mouse 
model of atherosclerosis by visualizing plaque inflammation. [111In]In-DOTA-JR11 uptake in 
human plaque tissue indicates the translational potential of this radioligand for human imaging. 
Recent success of SST2 imaging in atherosclerosis with DOTATATE, and a five times higher TBR 
of DOTA-JR11 than DOTATATE in oncological studies, make DOTA-JR11 an interesting ligand for 
further studies in atherosclerosis.
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Abstract
Purpose | Atherosclerotic plaque development and progression signifies a complex 
inflammatory disease mediated by a multitude of proinflammatory leukocyte subsets. Using 
single photon emission computed tomography (SPECT) coupled with computed tomography 
(CT), this study tested a new dual-isotope acquisition protocol to assess each radiotracer’s 
capability to identify plaque phenotype and inflammation levels pertaining to leukocytes 
expressing leukocyte function-associated antigen-1 (LFA-1) and the leukocyte subset of 
proinflammatory macrophages expressing somatostatin receptor subtype-2 (SST2). Individual 
radiotracer uptake was quantified and the presence of corresponding immunohistological cell 
markers was assessed.
Methods | Human symptomatic carotid plaque segments were obtained from endarterectomy. 
Segments were incubated in dualisotope radiotracers [111In]In-DOTA-butylamino-NorBIRT 
([111In]In-Danbirt) and [99mTc]Tc-[N0–1 4,Asp
0 ,Tyr3]-octreotate ([99mTc]Tc-Demotate 2) before 
scanning with SPECT/CT. Plaque phenotype was classified as pathological intimal thickening, 
fibrous cap atheroma or fibrocalcific using histology sections based on distinct morphological 
characteristics. Plaque segments were subsequently immuno-stained with LFA-1 and SST2 and 
quantified in terms of positive area fraction and compared against the corresponding SPECT 
images.
Results | Focal uptake of co-localising dual-radiotracers identified the heterogeneous 
distribution of inflamed regions in the plaques which co-localised with positive immuno-stained 
regions of LFA-1 and SST2. [111In]In-Danbirt and [99mTc]TcDemotate 2 uptake demonstrated a 
significant positive correlation (r=0.651; p=0.001). Fibrous cap atheroma plaque phenotype 
correlated with the highest [111In]In-Danbirt and [99mTc]Tc-Demotate 2 uptake compared 
with fibrocalcific plaques and pathological intimal thickening phenotypes, in line with the 
immunohistological analyses.
Conclusion | A dual-isotope acquisition protocol permits the imaging of multiple leukocyte 
subsets and the pro-inflammatory macrophages simultaneously in atherosclerotic plaque 
tissue. [111In]In-Danbirt may have added value for assessing the total inflammation levels in 
atherosclerotic plaques in addition to classifying plaque phenotype.
Keywords: Atherosclerosis, Inflammation, Carotid artery, Macrophage, Leukocyte, SPECT 
imaging, Dual-isotope
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Introduction
Atherosclerosis is derived from an inflammatory cycle that forms in response to the deposition 
of cholesterol rich, apolipoprotein B-containing lipoproteins in the intimal layer of the arterial 
wall (1). Inflammation controls all stages of the disease starting from the initiating atheroma 
development to the advanced, and potentially rupture-prone, plaque. Inflammation is 
instrumental in causing the clinical complications resulting in life-threatening stroke and 
myocardial infarction (2). Detection of this inflammatory activity is a high clinical priority. If the 
atherosclerosis-associated inflammation can be detected early a considerable reduction in the 
occurrence of these cardiovascular events could be made possible.
From the initiating phase of the disease, leukocytes, including monocyte-derived macrophages, 
lymphocytes and neutrophils, adhere to activated endothelium and are recruited into the 
developing atheroma (3). The proinflammatory leukocytes elicit a cascade of biological 
processes which renders the plaque susceptible to structural disruptions including fibrous 
cap ruptures (4). Following rupture, exposure of the thrombogenic plaque core to blood 
components can result in catastrophic cardiovascular events (5). The search for methods that 
can specifically target the inflammatory activity in atherosclerotic tissue and identify the high-
risk vulnerable plaque phenotype is a high clinical priority (6). 
Molecular imaging techniques including positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) have the unique capability to target specific 
biological processes at the molecular level. Numerous radiotracers, capable of targeting 
leukocytes and the inflammatory subsets, have been developed and imaged in human 
atherosclerotic plaque vessels (7). [111In]In-DOTA-butylamino-NorBIRT also known as [111In]
In-Danbirt is a novel radiotracer which can specifically target the leukocytes which express 
leukocyte function-associated antigen-1 (LFA-1). The value of this radiotracer has been 
initially demonstrated in in vivo animal studies utilising atherosclerosis disease models and 
also in a human atherosclerotic plaque case (8,9). Targeted imaging of atherosclerotic plaque 
with [68Ga]Ga-DOTA-[Tyr3]octreotate, a somatostatin receptor subtype 2 (SST2)-targeting 
radiotracer, detects the presence of activated (proinflammatory) macrophages (10). The 
clinical utilisation of this radiotracer has revealed its ability to achieve more focal imaging 
of inflamed atherosclerotic plaques in comparison to 2-deoxy-2-[18F]fluoro-D-glucose ([18F]
FDG) and thereby presenting another viable radiotracer (10-12). Clinical studies indicated that 
the detection of proinflammatory macrophages with a SST2 targeting radiotracer could help 
discriminate culprit plaques which have an overall higher uptake (10,11). Notwithstanding, 
there are conflicting results reported for this radiotracer. For example, comparing symptomatic 
culprit vessels to the contralateral vessels in the carotid vasculature can result in little to no 
differences in terms of uptake levels (13,14). The detection of ‘culprit’ inflamed vessels is partially 
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impeded by the paucity of information linking radiotracer uptake with respect to the specific 
plaque phenotype. 
Furthermore, the simultaneous use of two radiotracers, targeting different molecular 
processes, with dual-isotope acquisition SPECT imaging has provided an enhancement in 
the understanding of specific diseases (15-17). The utilisation of a dual-isotope acquisition 
protocol for atherosclerotic plaque tissue assessment may also provide improved information 
and in terms of aiding the detection of specific plaque phenotype. In this regard, this study 
aims to assess the added value of simultaneously targeting all leukocytes expressing LFA-1 
and the subset of proinflammatory macrophages expressing SST2 in order to identify plaque 
phenotype. To investigate this, a dual-isotope acquisition protocol of [111In]In-Danbirt and 
[99mTc]Tc-[N04, Tyr
3]-octreotate also known as [99mTc]Tc-Demotate 2 (18) is utilised to image ex vivo 
human carotid artery plaques. Additionally, the two radiotracers are compared to investigate 
if targeting all leukocytes provides pertinent information regarding the inflammatory status 




A cross-sectional molecular imaging study was performed with excised human carotid plaques. 
This exploratory research examines the uptake of two radiotracers pertaining to inflammatory 
populations involved in plaque progression. The plaque samples were obtained from seven 
atherosclerotic/symptomatic patients through endarterectomy procedures in the Erasmus 
MC, Rotterdam, The Netherlands, in a manner that conformed to the declaration of Helsinki 
and was approved by the hospital’s ethical research committee (MEC 2008-147). The carotid 
plaques were divided into segments of 2 mm thickness (n=23) for SPECT/CT imaging followed 
by immunohistochemistry. In another set of experiments, adjacent Carotid endarterectomy 
(CEA) segments (n=7) were sectioned for autoradiography followed by immunohistochemistry.
Radiolabelling
To target the two plaque’s inflammatory cell populations, [111In]In-Danbirt (MW=886.5 g/mole) 
(9) and [99mTc]Tc-Demotate 2 (18) were used (Figure 1). Each peptide was radiolabelled with a 
molar activity of 100 MBq/nmol, the radiochemical purity was >90% and the incorporation 
yield was >99%, as determined by high-pressure liquid chromatography and instant thin-
layer chromatography on silica gel. For [111In]In-Danbirt Quenchers (3.5 mM ascorbic acid, 3.5 
mM gentisic acid, 10 mM methionine) were present during labelling to prevent radiolysis of 
the radiotracers (19). The radiotracers were mixed in a solution of phosphate-buffered saline 
(PBS) containing 0.1% v/v bovine serum albumin (BSA). The plaque samples were incubated 
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in a mixed solution of the 2 radiotracers for 1h at room temperature. The plaque samples were 
then washed in PBS five times and assembled on a sealed perspex sample holder for scanning 
(Figure 2).
Figure 1 | A) Schematic of the two radiotracers targeting the receptors of leukocytes expressing leukocyte 
function-associated antigen-1 (LFA-1) and proinflammatory macrophages expressing somatostatin receptor 
subtype-2 (SST2). Chemical structures of the two radiotracers B) [
111In][In-DOTA-butylamino-NorBIRT] ([111In]
In-Danbirt) and C) [[99mTc]Tc-[N0-14,Asp
0,Tyr3]octreotate ([99mTc]TcTc-Demotate 2).
Figure 2 | A) Carotid plaque sample sectioned into 2 mm segments, B) incubation step involved immersing 
segment in mixture of dual-radiotracers [111In]In-Danbirt) and [99mTc]Tc-Demotate 2 and C) live and x-ray 
view of plaque segments (2 mm) mounted on a custom made holder for dual-isotope acquisition SPECT/CT 
scanning.
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Dual-isotope SPECT/CT imaging
For SPECT/CT imaging a VECTor5/CT system (MILabs B.V. Utrecht, The Netherlands) was 
used equipped with a high-energy ultra-high resolution mouse (HE-UHR-M) collimator. The 
system equipped with this collimator yields a 0.5 mm reconstructed SPECT resolution and a 
SPECT sensitivity of ~0.3 % (20,21). Each scan was acquired in list mode using the same scan 
parameters; spiral scan mode (22), and fine step mode at 30 seconds per bed position yielding 
a total acquisition time of 90 minutes for a field of view of 26 mm in diameter and 48 mm in 
length. This permitted scanning six 2 mm plaque segments, placed in the sample holder, during 
a single scan. For the CT, scanner settings were identical for all scans. Ultra-focus magnification 
was applied with a full scan angle, at 0.24 mA, 50 kV and 75 ms yielding a total scan time of 
15 minutes. The scans were reconstructed using filtered back projection at a resolution of 20 µm 
and down sampled to a reconstructed resolution of 80 µm for registration to SPECT scans. 
To accomplish quantification of 99mTc and 111In from dual isotope acquisitions, two separate 
reconstructions were performed. For 99mTc, a width of 20% of the gamma photopeak at 
140 keV was incorporated in the reconstruction. For 111In, two photopeak windows were set 
incorporating a width of 20% of the each gamma photopeak at 171 and 245 keV (23). For scatter 
correction the triple-energy-window method was (24) applied to each photo peak. Phantom 
experiments with dual-isotopes acquisitions for 99mTc and 111In were performed using the 
small-animal SPECT phantom SPECT IQ phantom which verified that the cross-talk within the 
relevant energy ranges was negligible (25).
SPECT scans were reconstructed at 0.2 mm voxel size using the Similarity Regulated Ordered 
Subset Expectation Maximization (SROSEM) algorithm (22). For this, 9 iterations, 128 subsets 
and a 3D Gaussian post filter of 0.5 mm (FWHM) were utilised. The VECTor5/CT system was 
calibrated to a standard of known activity that was measured in a dose calibrator, for absolute 
SPECT quantification for both radionuclides. All analysis of SPECT/CT scans was performed 
using PMOD (PMOD Technologies LLC, Zürich, Switzerland, Version 3.4). After imaging, the tissue 
segments were embedded in tissue-tek medium and stored at -80o C for immunohistological 
analysis after the radioactivity contained in the samples had decayed.
Immunohistological analyses
Each 2 mm plaque segment was cryo-sectioned into four 500 μm blocks in line with the 
SPECT resolution. Within each 500 μm block, sequential adjacent sections of 5 μm were made 
which overall yielded a total of 262 sections for quantification and analysis with respect to the 
SPECT/CT scan data. Sections were immunohistochemically stained with anti-LFA-1 (mouse 
anti-human CD11a 1:100 Biorad, MCA1848 clone 38), and anti-SST2A (human tissue: rabbit 
anti-human SSTR2A 1:50, clone UMB1, Abcam). Haematoxylin and eosin staining was used to 
determine the plaques overall structural morphology. The slides were photographed using a 
NanoZoomer Digital slide scanner (Hamamatsu, Photonics K.K). All images were exported to 
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BioPix iQ 3.3.5 software for quantitative analysis. The areas of positively stained LFA-1 and SST2 
were quantified using the dedicated hue, saturation and brightness selection tool and positive 
areas were measured as a percent fraction of the total plaque tissue area.
Plaque classification
The twenty-three carotid plaque segments were classified into 3 groups according to the 
American Heart Association (AHA) plaque classification (4), based on distinct morphological 
characteristics, identified with histology. Segments with pathological intimal thickening (n=4, 
17%) contained areas of inflammatory infiltration without necrotic tissue and were present 
in the bifurcation and internal carotid region. The fibrous cap atheroma segments (n=9, 
39%) morphologically consisted of a well-formed necrotic core and an overlying fibrous cap 
containing a high infiltration of inflammatory cells and were mainly found in the internal and 
common carotid regions. The fibrocalcific segments (n=10, 43%) contained large areas of 
calcification within the necrotic core and were all located in the bifurcation region.
Autoradiography
Segments of the carotid plaques, adjacent to those used for scanning, were cryo-sectioned 
at 10 μm and examined by ex vivo autoradiography and immunohistochemistry. Slides were 
washed in a washing buffer consisting of 1 M Tris-HCl (pH=7.6) containing 0.25% v/v BSA for 
10 minutes. The samples were incubated with 80 µL of radiotracer (10-9 M), with and without 
excess (10-6 M) matching unlabelled tracer for blocking. Slides were then washed and allowed 
to dry in an incubator at 37° C. High sensitivity phosphor screens were placed over the tissue 
sections for 48 h, after which the screens were read using a Packard Cyclone (Perkin Elmer) 
resolution 600 DPI. Quantification of the plaque sections was performed in terms of digital light 
units per mm2 (DLU/mm2) using Optiquant (Perkin Elmer).
Statistical analysis
Statistical analysis was performed using IBM SPSS statistics 21. Shapiro–Wilk tests were 
performed to assess the distribution of the data and select the most appropriate statistical 
test. Pearson’s correlation (r) and Spearman’s rho correlation (rs) were used to compare the 
correlation between the uptake levels of the radiotracers. A Mann-Whitney U test was used for 
non-parametric datasets to compare differences between uptake and positive area fraction for 
the three plaque morphology groups.
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Results
Expression of LFA-1 and SST2 in carotid plaque segments
Figure 3 illustrates the distinct morphological characteristics and positive immuno-stained 
regions of LFA-1 and SST2 in three plaque phenotypes classified as pathological intimal 
thickening, fibrous cap atheroma and fibrocalcific. In the inflamed fibrous cap atheroma 
phenotype, immunohistological analyses revealed large clusters of colocalising LFA-1 and SST2 
expressing inflammatory cells concentrated in the atheroma, at the fibrous caps and along 
shoulders (Figure 3 f, h) (Figure 4 c-d). Quantification of the areas with positive immuno-
staining for LFA-1 and SST2, within the representative 4 cryosections taken at intervals of 500 μm 
within each of the 2 mm plaque segments, revealed that the overall area fraction of LFA-1-
positive leukocytes was significantly larger in comparison with the area fraction positive for 
SST2-expressing macrophages independent of plaque phenotype. A large degree of variation 
was detected for fibrous cap atheroma segments in terms of the degree of positive LFA-1, 
reflecting the diverse inflammation status associated with this phenotype. The fibrous cap 
atheroma segments contained a significantly higher degree of inflammatory cells expressing 
LFA-1 compared to the fibrocalcific plaque segments and the pathological intimal thickening 
segments (Figure 5A). For SST2, fibrous cap atheroma segments and fibrocalcific segments 
contained comparable area fraction levels of SST2 positive cells. Pathological intimal thickening 
segments contained a significantly lower amount of SST2 positive area (Figure 5B). 
Radiotracer targeting of LFA-1 and SST2 in different plaque phenotypes 
assessed by SPECT
High-resolution SPECT images portray the local specificity of the dual-radiotracer’s binding to 
inflamed regions in the plaques which also co-localises with positive immuno-stained regions 
of LFA-1 and SST2 (Figure 3). An example of the focal high uptake of both radiotracers in the 
atheroma core and fibrous cap region of a fibrous cap atheroma plaque is illustrated in the 
SPECT images in Figure 4 whereby regions of [111In]In-Danbirt uptake co-localised with [99mTc]Tc-
Demotate 2 uptake. The [111In]In-Danbirt uptake is significantly higher compared to the [99mTc]
Tc-Demotate 2 for all plaque samples analysed in this cohort (p=0.001). There is a significant 
positive correlation in uptake between the radiotracers targeting the cells expressing LFA-1 and 
SST2 receptors (r=0.651; p=0.001) as illustrated in Figure 6. Quantification of each radiotracer’s 
total uptake (MBq/g) in each 2mm plaque segment with distinct plaque phenotype revealed 
that the highest uptake of [111In]In-Danbirt is correlated to plaque phenotype with fibrous 
cap atheroma (20.39 ± 3.97 MBq/g) (Figure 7A). The uptake is significantly higher compared 
to both the pathological intimal thickening (14.70 ± 3.23 MBq/g) and fibrocalcific plaque 
(14.05 ± 4.89 MBq). For [99mTc]Tc-Demotate 2 the mean uptake is significantly higher in the 
fibrous cap atheroma segments (7.98 ± 1.10 MBq/g) compared to the fibrocalcific segments 
(6.36 ± 2.39 MBq/g) (Figure 7B). However, a significant difference was not reached between the 
fibrous cap atheroma and pathological intimal thickening (6.38 ± 2.23 MBq/g) for the [99mTc]
Tc-Demotate 2 uptake (p=0.142). 
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Figure 3 | SPECT images of uptake for [111In]In-Danbirt (left panel 0–37 MBq/ml) and [99mTc]Tc-Demotate 2 
(right panel 0–17.5 MBq/ml) and the corresponding immunohistological sections classified according to 
plaque phenotype; pathological intimal thickening (A-D), fibrous cap atheroma (E-H) and fibrocalcific (I-L) 
(Scale bar=1mm).
Figure 4 | SPECT co-localisation of radiotracer uptake A) [111In]In-Danbirt) and B) [99mTc]Tc-Demotate 2 and 
corresponding immunohistochemistry sections with positive immunostaining for C) LFA-1 and D) SST2 in a 
plaque segment classified with fibrous cap atheroma phenotype (Scale bar=1 mm).
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 80
80 | Imaging of Inflammatory Cellular Protagonists in Human Atherosclerosis: a Dual-isotope SPECT Approach
Figure 5 | Box-plot of percent area fraction of positive immuno-staining for A) LFA-1 and B) SST2 in segments 
classified according to plaque phenotype (PIT, pathological intimal thickening; FC atheroma, fibrous cap 
atheroma and F.calc, fibrocalcific)
Figure 6 | Positive correlation between [99mTc]Tc-Demotate 2 and [111In]In-Danbirt and in terms of total uptake 
(MBq/g) per plaque segment
Comparing the sections with and without excess (10–6 M) radiotracer, revealed the substantial 
reduction in uptake in the CEA sections. The autoradiography analysis of [111In]In-Danbirt and 
[99mTc]Tc-Demotate 2 uptake also revealed the focal regions of high radiotracer binding in the 
fibrous cap atheroma segments in line with the immuno-positive regions for LFA-1 and SST2 
respectively (Figure 8).
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Figure 7 | Box-plot of radiotracer uptake (MBq/g) for A) [111In]In-Danbirt and B) [99mTc]Tc-Demotate 2 in each 
carotid plaque segment type classified according to plaque phenotypes; PIT, pathological intimal thickening; 
FC, fibrous cap atheroma and F.calc, fibrocalcific
Figure 8 | Uptake of dual-radiotracers in fibrous cap atheroma section; Autoradiography images showing 
focal regions of high radiotracer binding for A) [111In]In-Danbirt B) [99mTc]Tc-Demotate 2, C) Hematoxylin 
and eosin stain demonstrating morphology of fibrous cap atheroma section and corresponding immuno-
sections showing positive staining in the fibrous cap for D) leukocytes (LFA-1) and E) macrophages (SST2) 
(scale bar=1mm).
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Discussion 
In this study, a dual-isotope acquisition SPECT imaging protocol was tested to assess radiotracer 
uptake in distinct plaque phenotypes pertaining to two inflammatory cell populations involved 
in atherosclerosis. We demonstrated the unique capability of the [111In]In-Danbirt to identify 
inflamed plaque phenotype using human carotid plaques acquired through endarterectomy 
procedures. The mean [111In]In-Danbirt and [99mTc]Tc-Demotate 2 uptake was highest in 
fibrous cap atheroma plaque compared to pathological intimal thickening and fibrocalcific 
plaques. A comparison of the uptake for the two radiotracers revealed that [111In]In-Danbirt 
uptake was significantly higher compared to [99mTc]Tc-Demotate 2 uptake for all plaque 
samples analysed in this cohort, independent of plaque phenotype. These findings were in 
line with the immunohistological findings and detailed examination of the corresponding 
immunohistological sections revealed co-localization with LFA-1 and SST2 expressing cells. 
The atherosclerotic inflammatory activity is driven by multiple key leukocyte subsets including 
the monocyte derived macrophages, lymphocytes and neutrophils (26,27). In this regard, it is 
important to detect the presence of all leukocyte subsets, encapsulating the total inflammation 
activity, as a means for early atherosclerotic disease detection and potential prevention of 
adverse cardiovascular events (28). SPECT imaging showed focal uptake of [111In]In-Danbirt in 
the carotid plaque tissue which varied in accordance with the degree of inflammation that 
was heterogeneously distributed throughout the plaque as indicated by the co-localising areas 
of positive immuno-staining for LFA-1. The overall higher degree of [111In]In-Danbirt uptake 
compared to [99mTc]Tc-Demotate 2 uptake for all plaque samples analysed in this cohort is 
indicative of the successful detection of all leukocytes which are playing a key role in the disease 
progression. In a clinical setting, PET scanning is the preferred methodology in atherosclerosis 
imaging in terms of nuclear medicine due to the superior spatial resolution and quantification 
capabilities compared to clinical SPECT. For example, Moto et al. recently demonstrated that 
Danbirt labelled with the PET radioisotope Gallium-68 is highly stable in vitro in conditions that 
closely emulate those found during in vivo tracer delivery (9). For clinical use, the equivalents 
to SPECT imaging with [99mTc]Tc-Demotate 2 for targeting SST2 expressing proinflammatory 
macrophages in vivo are, [68Ga]Ga-DOTA-TATE and [64Cu]64Cu-DOTA-TATE which have both 
been shown to be potentially relevant tracers for plaque imaging with PET in cardiovascular 
disease patients.
From a pathological point of view, the atherosclerotic plaque composition is heterogeneous 
even within the same phenotype as identified for the [111In]In-Danbirt uptake in the fibrous 
cap atheroma segments. This is a consequence of the fact that inflammation levels vary 
considerably depending on the disease phase and inflammatory activity. Notably, this large 
variation in inflammation intensity was less pronounced in the [99mTc]Tc-Demotate 2 uptake, 
likely as proinflammatory macrophages (SST2) represents a small subset of the inflammatory 
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cells present in the plaque. While [111In]In-Danbirt imaging alone is very informative regarding 
atherosclerotic plaque phenotype detection, the ratio of [99mTc]Tc-Demotate 2 to [111In]In-
Danbirt advocates a potential role for dual-isotope acquisition in the assessment of plaque 
inflammation advancing the understanding towards the atherosclerotic disease development. 
For example, in the fibrous cap atheroma segments the ratio of [99mTc]Tc-Demotate 2 to [111In]
In-Danbirt is lower compared to the fibrocalcific segments. This implicates a higher level of 
involvement of the other leukocyte subsets with the proinflammatory macrophages in the 
fibrous cap atheroma phenotype compared to the more advanced fibrocalcific phenotype. 
In this regard, a dual-isotope acquisition protocol could provide added diagnostic benefit for 
the assessment of inflamed atherosclerotic vessels which could be useful for patient-specific 
therapeutic intervention.
Moreover, studies have reported the performance of [111In]In-Danbirt in vivo utilisingthe ApoE-/- 
mouse model. These studies provide evidence that the [111In]In-Danbirt is adequately taken 
up in local athero-prone regions, including the aortic arch. These atherosclerotic regions of 
uptake further co-localise with immunohistochemistry LFA-1 expressing cells (8). Importantly, 
the myocardial uptake signal is sufficiently low with respect to the background levels so as to 
not interfere with the imaging quantification of the aorta’s inflammation (8).
Pathological studies have classified the fibrous cap atheroma phenotype as the ‘culprit’ part of 
the vessel (29-31). Interestingly, in this study the intensity of radiotracer uptake correlated to 
plaque phenotype. The highest [111In]In-Danbirt uptake (MBq/g), correlates to inflamed fibrous 
cap atheroma plaque segments. This differentiates these highly inflamed plaque segments from 
fibrocalcific and pathological intimal thickening segments which are considerably less inflamed, 
and considered to have a lower risk of rupture. Similarly, the mean [99mTc]Tc-Demotate 2 uptake 
was also highest in the fibrous cap atheroma segments and also significantly higher compared 
to the fibrocalcific phenotype in line with the immunohistochemistry. Notwithstanding, to make 
a distinction in specific atherosclerotic plaque phenotype and the identification of vulnerable 
plaque characteristics remains a challenge based on the current radiotracers used in the clinic 
(13,32,33). For example, clinical studies have reported difficulty in differentiating symptomatic 
carotid vessels compared to the contralateral asymptomatic diseased side where there is a high 
degree of disease present in the contralateral carotid vessel (13). Consequently, delineation of 
the culprit vulnerable plaque is not always possible. The typical morphological features of a 
vulnerable plaque have been determined from pathological studies and can be characterised 
using MRI scanning. These include the presence of a large lipid-rich necrotic core, an overlying 
thin fibrous cap layer and intraplaque haemorrhage (34-36). However, morphological plaque 
data alone is also not enough for risk prediction of plaque rupture. In this regard, combining a 
measurement of the inflammation imaging (9) and the plaque morphology information from 
MRI may permit assessing the degree of inflammation activity coupled with vulnerable plaque 
characteristics in order to delineate high-risk vessels (37,38). 
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There are inherent limitations associated with this study that must be taken into account. 
The clinical translational aspect of the dual-isotope acquisition imaging protocol utilised in 
this ex vivo setting needs to be assessed in vivo. Notably, the acquisition of SPECT/CT imaging 
involved using a HE-UHR-M collimator which resulted in a considerably higher in-plane 
resolution of 0.5mm compared to the resolution capabilities of the clinical PET scanner which 
are approximately 10 times lower (33). In a clinical setting, the opposite occurs whereby 
PET resolution outperforms SPECT. Thus, PET isotopes Fluorine-18 and Gallium-68 are more 
favourable in the clinical setting compared to Indium-111 or Technitium-99m, although 
there is no current option for dual isotope imaging with the PET isotopes. Moreover, in order 
to incorporate a dual-isotope acquisition for SPECT imaging [99mTc]Tc-Demotate 2 was used 
simultaneously with [111In]In-Danbirt in this study. In the clinical setting, [68Ga]Ga-DOTA-TATE 
is utilised for PET imaging of SST2 expressing proinflammatory macrophages. The TATE differs 
from octreotate by the amino acid in position 3, being Tyr or Phe, respectively. It is important 
to take into account the application of different analogue radiotracers as they may lead to 
different quantitative results. Irrespective of the radiotracer applied, the fundamental principle 
of targeting the SST2 in atherosclerotic plaque tissue remains the same. Thus, the relative 
trend in uptake differences is expected to be comparable in the ex vivo and in vivo setting. 
In an in-vivo situation a larger degree of down scatter is to be expected in the [99mTc] window 
from [111In]. This will subsequently increase the background signal for [99mTc] but should not 
deter from the image quality when scatter is corrected for. An increased amount of scattering 
from the tissue in an in-vivo situation would also increase the background. The administration 
of two radionuclides will increase the radiation dose to the patient compared to the use of 
only one. Since both [99mTc] and [111In] radionuclides radiate mainly low to medium energy 
gamma rays, and the absence of alpha and beta radiation, radiation issues are not expected 
when a diagnostic amount of these radionuclides are administered to the patient. In terms of 
the analysis, in an attempt to normalise the plaque segments for comparison, the radiotracer 
uptake was reported with respect to the weight of each plaque segment. In one plaque 
segment, classified with the pathological intimal thickening phenotype, a negligible degree of 
inflammation was present whereby positive area fraction of staining for LFA-1 and SST2 were 
0.09% and 0.01% respectively on immunohistochemistry. As a consequence, it is likely that 
this ratio approach resulted in a false high uptake (MBq/g) for this one segment due to the 
extremely low uptake (MBq) in this segment and the low weight (g). Due to the small sample 
size in this phenotype group (n=4) a significant difference therefore was not reached for [99mTc]
Tc-Demotate 2 uptake compared to the fibrous cap atheroma segments. 
In conclusion, a dual-isotope acquisition SPECT scanning protocol was tested to assess the 
capability of [111In]In-Danbirt and [99mTc]Tc-Demotate 2 to determine atherosclerotic plaque 
inflammation and phenotype. The novel [111In]In-Danbirt detects the presence of multiple 
leukocyte subsets and appears to be able to strongly discriminate plaque phenotype of fibrous 
cap atheroma from pathological intimal thickening and fibrocalcific plaque segments. This 
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information provides a proof of concept basis for the [111In]In-Danbirt as a potential candidate 
for total inflammation imaging and plaque phenotype classification. Detecting the presence 
of all leukocytes in addition to leukocyte subset of proinflammatory macrophages may further 
enhance the pathological understanding of the inflammation involvement in atherosclerosis 
progression. Thus, further studies that evaluate the clinical benefit of utilising this radiotracer 
in vivo with clinical SPECT scanners are recommended.
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Abstract
Purpose | Many radioligands have been developed for the visualization of atherosclerosis by 
targeting inflammation. However, interpretation of in vivo signals is often limited to plaque 
identification. We evaluated binding of some promising radioligands in an in vitro approach in 
atherosclerotic plaques with different phenotypes.
Methods | Tissue sections of carotid endarterectomy tissue were characterized as early plaque, 
fibro-calcific plaque, or phenotypically vulnerable plaque. In vitro binding assays for the 
radioligands [111In]In-DOTATATE; [111In]In-DOTA-JR11; [67Ga]Ga-Pentixafor; [111In]In-DANBIRT; 
and [111In]In-EC0800 were conducted, the expression of the radioligand targets was assessed 
via immunohistochemistry. Radioligand binding and expression of radioligand targets was 
investigated and compared.
Results | In sections characterized as vulnerable plaque, binding was highest for [111In]In-
EC0800; followed by [111In]In-DANBIRT; [67Ga]Ga-Pentixafor; [111In]In-DOTA-JR11; and [111In]
In-DOTATATE (0.064 ± 0.036; 0.052 ± 0.029; 0.011 ± 0.003; 0.0066 ± 0.0021; 0.00064 ± 0.00014 
%Added activity/mm2, respectively). Binding of [111In]In-DANBIRT and [111In]In-EC0800 was 
highest across plaque phenotypes, binding of [111In]In-DOTA-JR11 and [67Ga]Ga-Pentixafor 
differed most between plaque phenotypes. Binding of [111In]In-DOTATATE was lowest across 
plaque phenotypes. The areas positive for cells expressing the radioligand’s target differed 
between plaque phenotypes for all targets, with lowest percentage area of expression in early 
plaque sections and highest in phenotypically vulnerable plaque sections.
Conclusions | Radioligands targeting inflammatory cell markers showed different levels of 
binding in atherosclerotic plaques and among plaque phenotypes. Different radioligands might 
be used for plaque detection and discerning early from vulnerable plaque. [111In]In-EC0800 and 
[111In]In-DANBIRT appear most suitable for plaque detection, while [67Ga]Ga-Pentixafor and 
[111In]In-DOTA-JR11 might be best suited for differentiation between plaque phenotypes.
Key words: atherosclerosis, inflammation, molecular imaging, autoradiography
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Introduction
Inflammation plays a crucial role in atherosclerotic plaque formation, progression, and 
destabilization (1,2). Therefore, inflammation is an attractive imaging target for plaque 
detection (3). Different plaque compositions present a different likelihood of rupture and 
subsequent cardiovascular events like myocardial infarction or stroke (4,5). Hence, there is a 
need for A) plaque detection, and B) a distinction between plaques in risk of rupture and in 
need of treatment as opposed to plaques which do not require intervention. As inflammation 
is a major factor in plaque destabilization, the level of inflammation might be used to identify 
vulnerable, rupture prone plaques.
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) Positron Emission Tomography/Computed 
Tomography (PET/CT) is taken up by metabolically active macrophages in plaque, and has 
been shown to detect plaque inflammation in vivo (6). However, [18F]FDG lacks specificity for 
inflammatory cells, and high uptake in the myocardium complicates image interpretation 
limiting the use of [18F]FDG in the coronary arteries (6,7). Therefore, recent research has focussed 
on the evaluation of other inflammation targeting radioligands. 
A number of radioligands have shown good results for plaque detection in recent literature 
(8-10). Especially imaging of the somatostatin subtype receptor 2 (SST2) and chemokine CXC 
motif receptor type 4 (CXCR4) seem promising. Coronary plaques were successfully detected 
by targeting SST2 on activated macrophages with [
68Ga]Ga-[DOTA, Tyr3]-octreotate ([68Ga]
Ga-DOTATATE) (11). DOTA-JR11 (DOTA-Cpac[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]-D- Tyr-
NH2) also targets SST2 but has a reported five times higher uptake in tumours than DOTATATE 
in oncological studies, and a more favourable biodistribution resulting in a higher target to 
background ratio (TBR) (12-15). Recently, we have reported on the successful use of [111In]
In-DOTA-JR11 for plaque detection in atherosclerotic mice (16). CXCR4 can be targeted 
with Pentixafor, which has shown favourable results for plaque visualization in a number of 
studies (17-21). We found that targeting leukocyte function associated antigen-1 (LFA-1) with 
radiolabelled DOTA-butylamino-NorBIRT (DANBIRT) was well suited for plaque detection (22,23). 
Moreover, we recently found higher uptake of radiolabelled DANBIRT than of an SST2-targeting 
radioligand ex vivo in human plaque tissue, as well as different levels of uptake in different 
plaque phenotypes (24). Another promising radioligand is radiolabelled DOTA-Bz-EDA-folate 
(EC0800), which binds to the Folate Receptor (FR). We and others showed the feasibility of FR 
imaging for plaque detection with a number of different radioligands (25-27). 
Previous studies mostly focused on plaque detection, and radioligand uptake is usually 
correlated to plaque presence, symptomatic plaque, or culprit plaque in the event of e.g. 
myocardial infarction. To our knowledge few studies relate radioligand uptake to plaque 
phenotype or composition (e.g. (28-30)). Ideally, future nuclear imaging methods relate 
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radioligand uptake to plaque phenotype, ultimately identifying plaques requiring intervention 
before a major adverse cardiovascular event occurs. Therefore, we investigated radioligand 
binding in human plaque samples with different phenotypes. 
Methods 
Study material
Human carotid plaques were obtained with informed consent via carotid endarterectomy 
from eight patients in the Erasmus MC. Sample acquisition was approved by the medical ethics 
committee of the Erasmus MC (MEC 2008-147). The samples were snap frozen in liquid nitrogen 
and stored in -80° C until the experiment started. The samples were embedded in Tissue-Tek 
O.C.T. compound (Sakura Finetek Europe B.V, Alpen aan den Rijn, The Netherlands) and stored 
in -80° C, after which tissue sections for in vitro binding assays and immunohistochemistry were 
sectioned at 4 mm intervals (n=37). 
Tissue sectioning
Tissue was sectioned at 5 µm for immunohistochemical (IHC) analysis and at 10 µm for in vitro 
binding assays (autoradiography (ARG)). In vitro binding assays were performed on adjacent 
sections for optimal comparison. Similarly, IHC was performed on sections adjacent to the 
sections used for in vitro binding assays. 
Radiolabelling
DOTATATE, DOTA-JR11 (provided by Helmut Maecke), DANBIRT, and EC0800 (provided by 
Auspep, Tullamarine, Australia) were labelled with [111In]InCl3 (Covidien, Petten, The Netherlands) 
with a molar activity of 200 MBq/nmol as described previously (31). Pentixafor (provided by 
Hans-Jürgen Wester) was labelled with Gallium-67 (Curium, Petten, The Netherlands), as 
Indium-111 labelling results in reduced binding affinity (32,33). Although Pentixafor is regularly 
labelled with Ga-68, we used Ga-67 due to its preferable characteristics for autoradiography 
in terms of half-life and resolution. Labelling with Gallium-67 was performed with a molar 
activity of 100 MBq/nmol as described (34). Radiochemical purity (>95%) and incorporation 
yield (>99%) were evaluated with high-pressure liquid chromatography and instant thin-
layer chromatography on silica gel. Quenchers were added to prevent radiolysis as described 
previously (35,36).
In vitro binding assays and competition binding assays
Sections were incubated for 1 hour with 10-9 M radiolabelled ligand. Specificity of the 
radioligands was demonstrated previously (11,16,17,37-41). Additionally, we confirmed specific 
binding in our tissue via competition binding experiments by blocking with 10-6 M unlabelled 
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compound. Slides were exposed to phosphor screens overnight and read with a phosphor 
imager (Cyclone, Perkin Elmer). 
Immunohistochemistry
Sections were immunohistochemically stained for SST2 (ab134152, Abcam), CXCR4 (ab124824, 
Abcam), LFA-1 (MCA1848, AbD SeroTec), or FR (AP5032a, Abgent). In short, sections were fixed 
in cold acetone for 5 minutes (SST2, CXCR4, LFA-1) or 10% formalin for 10 min (FR), endogenous 
peroxidase was blocked with 0.3% H2O2 for 30 minutes (SST2, LFA-1, FR) or 0.15% H2O2 for 
20 min (CXCR4), and non-specific binding was blocked with 1% BSA for 20 minutes (CXCR4) or 
2% normal goat serum for 20 minutes (SST2, LFA-1, FR). The primary antibody was omitted from 
the protocol in negative controls. 
Haematoxylin-eosin staining according to standard protocol was performed on the sections 
used for in vitro binding assays after radioactivity had sufficiently decayed. These sections were 
later used for plaque classification.
Plaque classification
Haematoxylin-eosin stained plaque sections where classified by two independent observers 
according to the criteria used in the adapted American Heart Association (AHA) classification 
(4,5,42). Plaque phenotypes were categorized into three groups: early plaque; fibro-calcific 
(FCALC) as stable plaque; and phenotypically vulnerable plaque.
Quantification and statistical analysis
Radioactive signal in plaque sections was quantified with Optiquant (Perkin Elmer) and 
expressed in digital light units per mm2 (DLU/mm2). Signal was corrected for radionuclide half-
life, and exposure time of the phosphor screen to the tissue sections. DLU/mm2 was converted 
to percentage added activity per mm2 (%AA/mm2) by normalizing data to standards included 
in the binding assays. 
For immunohistochemically-stained sections, Biopix software (Biopix AB, Gothenburg, 
Sweden) was used to calculate the percentage DAB (3,3’-diminobenzidine) positive area per 
tissue section.
The data were analysed with SPSS 21.0 (SPSS Inc, Chicago, IL). The data was tested for normality 
using the Shapiro-Wilk test. Differences between groups were analysed with the Kruskal-Wallis 
test, with Dunn’s post hoc test to account for multiple comparisons. P values below 0.05 were 
considered significant. Data are presented as mean ± standard deviation.
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Results
Plaque classification
Plaque sections were classified as early plaque (12 samples), stable plaque (10 samples), or 
phenotypically vulnerable plaque (15 samples) with an interobserver agreement of 97%.
Area of DAB positive staining & radioligand binding
Area of cells expressing radioligand targets
Figure 1A shows the average DAB-positive area for each studied radioligand target and plaque 
category. All radioligand targets were expressed in larger areas in more advanced plaques 
than in early plaques (Figure 1A). No significant differences in areas were observed in early 
plaque sections. In FCALC plaque sections, the areas containing LFA-1 expressing cells were 
significantly higher than the areas of FR expressing cells (p<0.05). In vulnerable plaque sections, 
FR was expressed in significantly less area than LFA-1 (p<0.001) and CXCR4 (p<0.001). 
Binding of [111In]In-DANBIRT and [111In]In-EC0800 was highest across plaque phenotypes
Figure 1B shows radioligand binding of the different radioligands across plaque categories. 
Binding of [111In]In-DANBIRT and [111In]In-EC0800 was highest, followed by [67Ga]Ga-Pentixafor, 
[111In]In-DOTA-JR11, and [111In]In-DOTATATE. In sections of early plaque lesions, [111In]
In-DOTATATE signal (0.00047 ± 0.00017 %AA/mm2) was significantly lower than [67Ga]Ga-
Pentixafor (0.0053 ± 0.0012 %AA/mm2 p<0.01), [111In]In-DANBIRT (0.026 ± 0.013 %AA/mm2) 
and [111In]In-EC0800 (0.027 ± 0.018 %AA/mm2) signal (p<0.001). [111In]In-DOTA-JR11 signal 
(0.0027 ± 0.00085 %AA/mm2) was also significantly lower than [111In]In-DANBIRT and [111In]In-
EC0800 signals (p<0.001). 
In FCALC sections, [111In]In-DOTATATE signal (0.00053 ± 0.000076 %AA/mm2) was also 
significantly lower compared to [67Ga]Ga-Pentixafor (0.0066 ± 0.0014 %AA/mm2 p<0.05), [111In]
In-DANBIRT (0.032 ± 0.015 %AA/mm2) and [111In]In-EC0800 (0.068 ± 0.050 %AA/mm2) (p<0.001). 
[111In]In-DOTA-JR11 signal (0.0033 ± 0.0015 %AA/mm2) was also significantly lower than [111In]
In-DANBIRT (p<0.01) and [111In]In-EC0800 (p<0.001). 
In vulnerable plaque sections, [111In]In-DOTATATE signal (0.00064 ± 0.00014 %AA/mm2) 
was again lower than that of [67Ga]Ga-Pentixafor (0.011 ± 0.003 %AA/mm2 p<0.05), [111In]In-
DANBIRT (0.052 ± 0.029 %AA/mm2) and [111In]In-EC0800 (0.064 ± 0.036 %AA/mm2 p<0.001). 
[111In]In-DOTA-JR11 signal (0.0066 ± 0.0021 %AA/mm2) was significantly lower than those of 
[111In]In-DANBIRT (p<0.01) and [111In]In-EC0800 (p<0.001), whereas [111In]In-EC0800 signal was 
significantly higher than [67Ga]Ga-Pentixafor signal (p<0.05).
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Radioligand binding was higher in advanced plaque phenotypes than in early plaque
Figure 2 shows radioligand binding per radioligand across plaque phenotypes. All radioligands 
showed more signal in advanced than in early plaque sections. [111In]In-DOTATATE signal 
was significantly higher in vulnerable sections than in sections classified as early plaque 
(0.00064 ± 0.00014 and 0.00047 ± 0.00017 %AA/mm2 p<0.01). [111In]In-DANBIRT and [111In]In-
EC0800 also had significantly higher signal in vulnerable sections compared to early plaque 
(0.052 ± 0.029 vs 0.026 ± 0.013 and 0.064 ± 0.036 vs 0.027 ± 0.018 %AA/mm2, respectively. 
p<0.05). [111In]In-DOTA-JR11 bound significantly more to vulnerable sections compared 
to early (0.0066 ± 0.0021 vs 0.0027 ± 0.00085 %AA/mm2 p<0.001) and FCALC sections 
(0.0033 ± 0.0015 %AA/mm2 p<0.01). [67Ga]Ga-Pentixafor showed a similar binding pattern as 
[111In]In-DOTA-JR11, with binding in vulnerable sections being higher (0.011 ± 0.003 %AA/mm2) 
than binding in early plaque sections (0.0053 ± 0.0012 %AA/mm2 p<0.001) and FCALC sections 
(0.0066 ± 0.0014 %AA/mm2 p<0.05).
[111In]In-DOTA-JR11 binding is higher than [111In]In-DOTATATE
There was a clear difference in binding amongst the SST2 targeting radioligands, but the 
differences were not statistically significant. [111In]In-DOTA-JR11 showed a 5.6 fold higher signal 
than [111In]In-DOTATATE in early plaque sections, a 6.3 fold higher signal in stable plaques, and 
a 10.2 fold higher signal in vulnerable plaque sections (Figure 1B).
Location of binding differs between radioligands
Figure 1C illustrates the differences in radioligand signal and target receptor distribution in 
vulnerable plaque sections. Figure 2 displays representative examples of radioligand binding 
and target receptor distribution. Expression of SST2 and signal of [
111In]In-DOTATATE and [111In]
In-DOTA-JR11 was mostly located in cap areas of plaque. [67Ga]Ga-Pentixafor signal and CXCR4 
expression was located in cap areas as well as around calcified nodes. [111In]In-DANBIRT signal 
and LFA-1 expression was visible on the medial side of the necrotic core, in cap areas, and 
around calcium deposits. Signal of [111In]In-EC0800 and expression of FR was mostly located at 
areas close to the artery lumen, and in areas at the edge of the tunica media. Signal of [67Ga]
Ga-Pentixafor and [111In]In-DOTA-JR11 differed most between vulnerable plaque sections and 
early or stable plaque sections.
Figure 2 | % added activity/mm2 (%AA/mm2) in plaque sections for each radioligand across plaque categories. 
Representative examples of IHC and ARG are shown below each radioligand graph. Note that the graphs and 
autoradiograms are not uniformly scaled, but scaled for visibility per image. DOTATATE, DOT-JR11, DANBIRT, 
and EC0800 were labelled with Indium-111, Pentixafor was labelled with Gallium-67. ARG,autoradiography, 
IHC,immunohistochemistry, SST2,somatostatin subtype receptor 2, CXCR4, chemokine CXC motif receptor 
type 4; LFA-1, leukocyte associated antigen 1; FR, folate receptor; * indicates p<0.05, ** indicates p<0.01, *** 
indicates p=<0.001.
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Discussion
A large number of inflammation targeted radioligands has been studied for atherosclerotic 
plaque detection (8-10). We examined the binding of several promising inflammation targeted 
radioligands and the distribution of cells expressing the radioligand targets in sections of 
different plaque phenotypes. For all radioligands, we found higher levels of binding in advanced, 
vulnerable plaque sections than in early plaque sections. The same pattern was visible for the 
portion of plaque area expressing the radioligand targets. Moreover, we found significantly 
higher binding of [111In]In-DANBIRT and [111In]In-EC0800 across plaque phenotypes compared 
to the other radioligands. Binding of [111In]In-DOTA-JR11 and [67Ga]Ga-Pentixafor differed most 
between vulnerable plaque sections and sections of the other plaque phenotypes.
We studied in vitro binding of radioligands in tissue sections of atherosclerotic plaque. Binding 
differs strongly between in vitro assays and in vivo. The mechanisms of uptake could differ, 
expression of receptors might be influenced differently in vivo, and radioligands in vivo often 
only get a limited number of passes along tissues to reach their target receptor before being 
cleared from the blood. Moreover, background signal from other tissues might be high in vivo. 
Also, the effects of freezing or tissue degradation can play a role in in vitro binding. Despite these 
important differences between in vitro and in vivo, our approach provides valuable information. 
The targets are optimally reachable in 10 µm sections, the radioligands get sufficient time to 
bind to available receptors, and there are no imaging artefacts related to resolution, spill over, 
or attenuation. Therefore, our approach mimics the potential binding of the radioligands in the 
examined tissues and might give an indication of an idealized uptake that might be achieved 
in vivo.
Recent studies suggest that SST2 targeting with DOTATATE is a viable strategy for plaque 
detection (37,43-47). Tarkin and colleagues showed that [68Ga]Ga-DOTATATE could better 
discriminate between high-risk and low-risk plaques compared to [18F]FDG (11). However, 
another study found that imaging with [68Ga]Ga-DOTATATE could not differentiate between 
symptomatic plaque and the contralateral artery, and in line with these results found no SST2 
expressing cells in plaque (48). Furthermore, the aorta to blood ratio of [68Ga]Ga-DOTATATE 
found by Rinne et al. (44) was lower than one, which further indicates that in vivo imaging 
with this radioligand requires optimization. Our in vitro results could in part explain these 
discrepancies. We clearly demonstrated the presence of SST2 expressing cells in human carotid 
tissues and found localized binding of [111In]In-DOTATATE. However, [111In]In-DOTATATE signal 
was much lower than signal of the other studied radioligands. Moreover, binding of [111In]In-
DOTATATE between sections of different plaque phenotypes showed the least difference of 
all investigated radioligands. Although imaging of atherosclerosis with DOTATATE is valid for 
plaque detection, these results confirm the need for further optimization.
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DOTA-JR11 could provide a significant improvement in SST2 imaging. Oncological studies 
reported a much higher uptake and TBR of DOTA-JR11 than DOTATATE, ranging from 
2–20 fold more (12–15). The mechanism for this difference in uptake between the SST2 
targeting radioligands remains to be elucidated, it is hypothesized that antagonistic ligands 
such as DOTA-JR11 bind more binding sites than agonistic ligands such as DOTATATE (49). We 
recently found that [111In]In-DOTA-JR11 could be used to detect atherosclerotic plaques in vivo 
in an animal model of atherosclerosis with high specificity (16). Our current results showed 
a 10.2 fold higher signal of [111In]In-DOTA-JR11 over [111In]In-DOTATATE in vulnerable plaque 
sections. Moreover, binding of [111In]In-DOTA-JR11 differed significantly between plaque 
phenotypes, which indicates that DOTA-JR11 could be useful to discriminate between different 
plaque phenotypes. These results strongly suggest that imaging SST2 with DOTA-JR11 is a 
relevant strategy for plaque detection and characterization.
Similarly to DOTA-JR11, we found high binding of [Ga67]Ga-Pentixafor, and significantly 
different binding between plaque phenotypes. In line with our findings, Derlin et al. (18) found 
more CXCR4 expressing cells in symptomatic plaques than in asymptomatic plaque tissue. 
Similar findings were reported via mRNA and IHC assays, with more CXCR4 expression in late 
stage plaque (21,50,51). Combined with our data these and other studies mark Pentixafor as an 
important radioligand for atherosclerosis detection and characterization (17,19,20,52-54). 
[111In]In-DANBIRT binding differed strongly from binding of [111In]In-DOTATATE, [111In]In-DOTA-
JR11, and [Ga67]Ga-Pentixafor. Binding of [111In]In-DANBIRT was located at the same locations, 
but was in addition high at the medial side of the necrotic core. The high signal and binding in 
more areas compared to the other radioligands was in line with the target findings. Whereas 
SST2 and CXCR4 are expressed on a subset of inflammatory cells, LFA-1 can be considered a 
leukocyte marker and is therefore present on various types of inflammatory cells. Earlier studies 
showed high specificity of DANBIRT, and in vivo experiments in animal models of atherosclerosis 
show promising results (23,40,55). Moreover, our group also found different levels of [111In]In-
DANBIRT uptake in phenotypically different plaque tissues ex vivo (24). Combined with the high 
binding of [111In]In-DANBIRT in our tissue sections this suggests that this radioligand is relevant 
for plaque detection and characterization.
[111In]In-EC0800 binding was highest across plaque phenotypes in the examined panel of 
radioligands, and its signal was significantly higher in sections classified as vulnerable plaque 
than in early plaque sections. Imaging of FR is extensively studied in atherosclerosis with 
different imaging probes in vivo in animal models of atherosclerosis (26,27,56,57) and in vitro 
in human tissue (27,58-60). Müller et al. found higher FR expression and higher signal of a FR 
targeting radioligand in sections of plaque compared to normal arterial wall, but no significant 
differences between sections of plaque classified as stable or vulnerable (60). In contrast, our 
group showed in vivo uptake of [111In]In-EC0800 in a mouse model of atherosclerosis, and found 
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higher [111In]In-EC0800 uptake in stable plaque compared to vulnerable plaque (26). Jager et al. 
linked FR expression to presence of M1-like macrophages (58). None of the studies examining 
in vitro expression or imaging of FR reported uptake or binding in the edges of tissue sections, 
like we observed in our study. FR staining confirmed FR expression in these locations, therefore 
binding of EC0800 in these locations is not an artefact. However, additional staining for CD68 
(data not shown) shows no presence of macrophages in these areas. FR expression is not 
limited to macrophages, further studies into the binding or uptake of FR targeting radioligands 
are therefore recommended. 
Few imaging studies make head-to-head comparisons between radioligands or relate 
radioligand uptake to plaque composition beyond identification of clinically identified culprit 
plaque. Our and various other studies can aid the development of new imaging strategies (29,44), 
and are useful to translate in vivo signal to characterization of plaque status. For example, Rinne 
et al. examined multipe radioligands in an in vivo model of atherosclerosis, and Borchert et 
al. investigated uptake of multiple radioligands in vitro in different leukocyte subtypes (29,44). 
Such studies can be used to identify which radioligands are most suited for plaque detection 
and for identification of vulnerable plaques in need of intervention. Our results warrant further 
clinical translation studies of plaque imaging using these new radioligands.
Conclusion
This in vitro study indicates that DANBIRT and EC0800 are most suited for plaque detection given 
the high levels of binding. DOTA-JR11 and Pentixafor are best suited to differentiate between 
stable and vulnerable plaque based on the high differences in binding of these radioligands in 
phenotypically stable and vulnerable plaques. As in vivo studies with these radioligands show 
promising results for plaque detection, our findings indicate that further clinical evaluation for 
plaque characterization are warranted.
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Cardiovascular disease remains the leading cause of death worldwide (1,17), the incidence of 
cardiovascular disease is expected to further increase due to the rise in longevity and increase 
in western type life style in Asian and South American countries (18). As atherosclerosis is 
the main contributor to ischemic cardiovascular events like myocardial infarction and stroke 
(6), diagnosis and treatment of atherosclerotic plaques remains of paramount importance. 
Innovative detection methods such as those discussed in this thesis (see Figure 1 for a visual 
overview) may guide treatment to prevent major adverse cardiovascular events. Further 
research, as discussed in the final chapters of this thesis, may be used to identify the most 
promising imaging methods to be evaluated in clinical studies. 
Figure 1 | A schematic overview of the work discussed in this thesis. Chapter 2 discusses relevant 
considerations in preclinical radionuclide evaluation. The studies presented in Chapters 3 and 4 focussed on 
detection of inflammatory cells in atherosclerotic plaque. Chapter 5 shows a novel protocol, which combines 
the approaches discussed in Chapters 3 and 4. The work presented in Chapter 6 assessed the prevalence 
and distribution of the targets of a selection of promising radioligands, and how the respective radioligand 
binding localizes in these tissues.
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Nuclear medicine has improved patient care in many ways in the past decades. The use 
of nuclear imaging procedures still increases because of rising incidence of cancer but also 
increasing prevalence of cardiovascular disease. Application of imaging procedures has become 
fairly standardized, and widespread expertise for existing imaging platforms and radioligand 
applications is present. However, testing of novel methods as discussed in this thesis requires 
new perspectives, new approaches, and often new expertise. In Chapter 2 we reviewed a 
number of the important considerations regarding the use of small animal models for studying 
novel imaging techniques for atherosclerosis. When performing new imaging procedures 
on the edge of what is possible regarding e.g. spatial resolution and sensitivity, optimizing 
every aspect of imaging is necessary to reach the highest standard. We firstly discussed the 
need and potential for novel imaging methods in atherosclerosis imaging. Secondly, we 
described animal models of atherosclerosis, and discussed differences between human and 
murine atherosclerosis regarding aspects of plaque composition and location, as well as 
differences between immune cell subsets. We also covered different technical considerations 
like quantification and image reconstruction and discussed opportunities in hybrid imaging 
and differences between clinical and preclinical PET and SPECT. Finally, we argued which traits 
are relevant when developing novel radiolabelled tracers and provided a future outlook on 
preclinical imaging.
In the following two chapters we covered two novel imaging approaches for plaque 
evaluation. In Chapter 3 we evaluated the novel radioligand [111In]In-DANBIRT, a radioligand 
targeting Leukocyte Function-associated Antigen-1 (LFA-1). This is a highly attractive imaging 
target because it is present on all leukocytes. Whereas many studies investigate radioligands 
targeted at macrophage subsets, this target can give a complete overview of the inflammatory 
status of a plaque. This is relevant as many leukocytes, such as neutrophils, dendritic cells, and 
monocytes play a role in plaque formation and destabilization besides macrophages (19-22). In 
this study we found that [111In]In-DANBIRT successfully visualized plaque in vivo in mice with 
a high target to background ratio (TBR) and high specificity. Moreover, we confirmed that the 
uptake of the radioligand, and expression of LFA-1, co-localizes with regions of inflammation 
as evidenced by staining for macrophages with immunohistochemistry (CD68). As we showed 
this co-localization and specificity in both human and mouse tissue, we concluded that this 
radioligand has high potential for plaque imaging in a clinical study.
In Chapter 4 we report our findings on [111In]In-DOTA-JR11, a radioligand which targets soma-
tostatin receptor subtype 2 (SST2). SST2 is highly expressed on activated macrophages and 
therefore it is an attractive imaging target to detect inflammation in plaques. As discussed 
in the previous paragraph, many studies focus on macrophages for atherosclerotic plaque 
detection as macrophages are the most prevalent inflammatory cell type in plaques. Moreover, 
radioligands targeted at more ubiquitously expressed inflammatory markers, like [18F]FDG, 
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often lack target specificity. Earlier SST2 imaging studies with [
68Ga]Ga-[DOTA,Tyr3]-octreotate 
(DOTATATE) in patients have successfully visualized plaques in vivo in the coronary (23) and 
carotid (24) arteries. DOTA-JR11 is a somatostatin receptor antagonist however, as opposed to 
most radioligands like [DOTA,Tyr3]-octreotate (DOTATATE), which are receptor agonists. Recent 
studies (reviewed in (25)) have reported that DOTA-JR11 has a five to ten times higher uptake 
than DOTATATE in tumour tissue. We therefore considered DOTA-JR11 a valuable candidate to 
improve plaque imaging, as higher radioligand uptake would lower the detection threshold. 
We examined the feasibility of plaque imaging with [111In]In-DOTA-JR11 in vivo in a mouse 
model of atherosclerosis and ex vivo in human and mouse plaque tissue. We found high levels 
of specific uptake in vivo, which was confirmed by ex vivo and in vitro experiments. Given the 
earlier results on imaging SST2 in atherosclerosis, we believe that clinical studies with DOTA-
JR11 and head to head comparisons between DOTATATE and DOTA-JR11 are justified.
Current nuclear imaging most often applies a single radioligand for an imaging procedure. We 
hypothesize that using multiple radioligands in one scan procedure could be an effective way 
to more thoroughly assess disease characteristics in clinical practice and help to identify which 
plaques may require intervention before an acute event occurs. In Chapter 5 we described our 
first step in this direction. In this study, we use an imaging protocol which visualizes both targets 
described in Chapters 3 and 4 by combined SPECT/CT. Both LFA-1 and SST2 show high potential 
as targets for clinical plaque identification. Therefore, an imaging protocol which ascertains 
the degree of inflammation by imaging LFA-1 and provides information on macrophages by 
imaging SST2 could be of value to differentiate between less-inflamed or calcified plaque via 
CT, inflamed plaque via LFA-1 imaging, and plaque vulnerability by adding SST2 imaging. Our 
results firstly showed that such a combined imaging protocol is feasible in human plaque 
tissue. Secondly, we observed that [111In]In-DANBIRT is taken up in all plaque types, with a 
higher uptake in phenotypically vulnerable plaques. Thirdly, we found that although imaging 
SST2 with [
99mTc]Tc-[N4,Asp
0,Tyr3]-octreotate ([99mTc]Tc-Demotate 2) was feasible, there were 
no significant differences between different plaque phenotypes. Finally, we confirmed that 
radioligand uptake co-localized with immunohistochemistry for the radioligand targets. These 
results indicate that dual isotope imaging is feasible in atherosclerosis, that [111In]In-DANBIRT 
has discriminatory power for different plaque phenotypes, whereas the SST2 targeting moiety 
does not discriminate between plaque phenotypes in this research setting.
Assessment of plaque characteristics is an important research aim besides plaque detection. 
In Chapter 6 we present results for the most promising radioligands in our field. We examined 
[111In]In-DOTATATE and [111In]In-DOTA-JR11 for SST2, [
111In]In-DANBIRT for LFA-1, [67Ga]Ga-
Pentixafor for chemokine CXC motif receptor type 4 (CXCR4), and [111In]In-EC0800 for the Folate 
Receptor (FR). We used in vitro autoradiography and immunohistochemistry to examine the 
presence of radioligand targets in different phenotypes of human plaque as well as binding 
of radioligands to these targets. Our results indicated that the radioligands targeting FR and 
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LFA-1 had the highest radioligand binding across all plaque phenotypes and may therefore be 
most useful for plaque detection in clinical practice. We also found that these two radioligands 
bound most in phenotypically vulnerable plaque phenotypes, although [111In]In-EC0800 also 
has high levels of binding in phenotypically stable plaques. We found similar patterns of uptake 
across plaque phenotypes for the radioligands targeting SST2 and CXCR4, although uptake 
was several factors lower than with [111In]In-DANBIRT and [111In]In-EC0800. However, binding 
of [111In]In-DOTA-JR11 and [67Ga]Ga-Pentixafor differed also between stable and vulnerable 
plaque, potentially allowing better discrimination between these plaque phenotypes. To 
complement the research questions raised in Chapters 4 and 5, we used both the SST2 agonist 
and antagonist. Here we found that the receptor agonist [111In]In-DOTATATE underperformed 
compared to [111In]In-DOTA-JR11. Although in vitro uptake cannot directly be related to in vivo 
radioligand behaviour and uptake, we recommend that the radioligands directed towards the 
FR and LFA-1 are most beneficial to be pursued for plaque detection. 
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Discussion and future outlook
Discussion
Imaging of inflammation to detect atherosclerosis. 
Imaging of inflammation has large potential for atherosclerotic plaque detection; the plethora 
of reviews written on this subject confirm the interest in this imaging strategy (16,26,35-
37,27-34). Inflammatory cells play a key role in the initiation, progression, and destabilization 
of atherosclerotic plaque (5,38) and therefore present relevant imaging targets. Imaging of 
inflammation has already proven its value in studies with [18F]FDG (12,13,39-44), as this tracer 
was able to detect inflamed plaque despite the limitations of this tracer. Given the advantages 
of more specific radioligands, the clinical value can be considered even higher with currently 
researched radioligands. 
Although different radioligands have different strengths for atherosclerosis imaging, the best 
radioligand is the radioligand which is readily available for patients. In this respect especially 
Pentixafor (targeting CXCR4) and DOTATATE (targeting SST2) are relevant to highlight (see 
references (23,45-47)). DOTATATE is approved for clinical use in oncology by regulatory bodies 
(like FDA and EMA), making it more readily available for evaluation in patients suffering from 
other diseases. Pentixafor is currently under investigation, and has already shown promising 
results in patients with atherosclerosis (45,47-49). 
Despite the great potential, it is important to acknowledge that atherosclerosis is a complex 
disease process. Other factors like neo-angiogenesis, calcification, and hypoxia also play 
a major role (5) and could therefore be considered as imaging targets. It is unlikely that the 
inflammatory status of a plaque gives a complete view of plaque vulnerability, and some 
plaques will have inflammatory levels below the detection threshold. It is therefore important 
to combine inflammatory imaging with other factors of plaque vulnerability. A number of 
studies review other aspects of plaque formation and composition (30,31,50-52). A number of 
these imaging targets are reviewed in Chapter 2.
 
Imaging LFA-1 and SST2
SST2 and LFA-1 are the main targets for which preclinical in vivo results are documented in 
this thesis (Chapters 3 & 4). The results of [111In]In-DOTA-JR11 and [111In]In-DANBIRT both 
show highly focal radioligand uptake at plaque locations, and display specificity for plaque in 
competition binding assays. Imaging of SST2 with DOTATATE shows major promise in a number 
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of studies (23,24,53-58). Because JR11 has a 5–10 times higher tumour uptake in oncological 
studies (reviewed in (25)), it has high potential to also improve SST2 imaging in atherosclerosis. 
Despite the high promise of SST2 imaging, a few uncertainties remain. Wan et al. showed 
that symptomatic carotid plaque could not be distinguished from the non-symptomatic 
contralateral plaque with [Ga68]Ga-DOTATATE (24), hinting that [Ga68]Ga-DOTATATE might be 
poorly suited for characterization of symptomatic carotid plaques. Moreover, in a mouse model 
of myocardial infarction Thackeray et al. showed a rapid wash-out of [Ga68]Ga-DOTATATE from 
inflamed myocardium resulting in a low TBR of 0.10 ± 0.03 (59), which suggests that [Ga68]Ga-
DOTATATE is not well suited to image inflammation in the myocardium. This could indicate 
that [Ga68]Ga-DOTATATE binds only shortly to SST2 on macrophages. Although the results found 
in these studies are not in conflict with the notion that DOTATATE and SST2 imaging can be 
used to detect plaques, they do indicate that further studies into the binding of DOTATATE in 
atherosclerotic tissue are required. This is in accordance with the in vitro study described in 
Chapter 6 of this thesis, where 111In-labelled DOTATATE had the lowest uptake in any plaque 
type compared to 111In-labelled DOTA-JR11, DANBIRT, EC0800, or 67Ga-pentixafor. Moreover, 
DOTATATE showed little difference in uptake between different plaque phenotypes. How our 
results and those of Wan et al. and Thackeray et al. (24,59) relate to the more promising studies 
performed with DOTATATE (23,57,60) remains to be investigated. 
A limited number of studies is available on nuclear imaging of LFA-1. Poria et al. reported 
high specificity of DANBIRT for murine and human LFA-1, and showed favourable kinetics 
of DANBIRT (61). Mota and colleagues showed increased binding of [Ga68]Ga-DANBIRT to 
neutrophils following an inflammatory stimulus, and reported increased binding in aorta, 
mouse serum, and leukocytes in biodistribution studies in a mouse model of atherosclerosis 
on high fat diet (62). Moreover, they also reported on increased aortic DANBIRT uptake over 
time during high fat diet in ApoE-/- mice. Mumaw et al. used [111In]In-DANBIRT to visualize an 
increase of inflammation in ferret lungs after exposure to polluted air, and found that this 
was in accordance with the number of neutrophils present in bronchio-alveolar lavage fluid 
(63). These and our own studies show the potential of DANBIRT for imaging LFA-1, and how 
DANBIRT might be used in other patho-physiologies as well, as LFA-1 becomes more attractive 
as an imaging target given the large interest in LFA-1 as a therapeutic target in a range of 
diseases (64-70). The affinity state of LFA-1 is strongly influenced by chemokines (as discussed 
in (71)), triggering a more receptive affinity state of LFA-1 around sites of inflammation. This 
might result in larger abundance of high affinity LFA-1 on leukocytes in inflamed areas, which 
is reflected by the high TBR found in Chapter 3. 
Comparing radioligands and relating uptake to plaque phenotypes
Most studies evaluate single radioligands, and imaging procedures in clinical practice also 
mostly use a single radioligand only. The differences in radioligand uptake shown in Chapters 
5 & 6 show that inflammation imaging to detect plaque can be used as an imaging method 
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which visualizes different aspects of plaque inflammation, thus vulnerability. While plaque 
detection remains an important goal, investigating how radioligand uptake is related to 
plaque phenotypes is important also. Table 2 shows, based on the research documented in this 
thesis, which of the investigated radioligands are more suited for plaque detection or plaque 
characterization. Moreover, comparing different radioligands in the same study is important to 
reliably compare how radioligands perform in terms of e.g. TBR or retention in plaque. Only a 
few studies compare radioligands or investigate radioligand binding more deeply (e.g. 55,73). 
Table 1 | Suitability of the radioligands discussed in this thesis in regards to plaque detection or plaque 
characterization. 
Radioligand Target Plaque detection Plaque characterization
[111In]In-DOTATATE SST2 + +
[111In]In-DOTA-JR11 SST2 ++ ++++
[67Ga]Ga-Pentixafor CXCR4 ++ ++++
[111In]In-DANBIRT LFA-1 ++++ +++
[111In]In-EC0800 FR ++++ +++
SST2, somatostatin receptor subtype 2; LFA-1, leukocyte function-associated antigen-1; CXCR4, chemokine CXC motif 
receptor type 4; FR, folate receptor.
Future outlook 
The search continues
A large array of radioligands targeting inflammation is assessed. Despite these efforts, the holy 
grail in atherosclerosis imaging, differentiation between stable and vulnerable plaque, has not 
been found yet. Designing and evaluating novel radioligands remains a relevant approach in 
this quest. However, a shift in focus away from the study of individual radioligands might be 
beneficial. Three avenues of research are relevant in this respect:
1. More clinical studies. Reviews on radioligands show that many different radioligands are 
evaluated in preclinical settings (30,31,50,51). Despite promising preclinical results, a limited 
number of studies is available of radioligands studied in patients. This is largely due to the 
costly and time intensive nature of patient studies, including requirements from Ethical 
Committees and regulatory authorities (FDA/EMA) to guarantee safety and efficacy. New 
approaches used by the FDA, such as requirements for exploratory investigational new 
drugs (eINDs), may facilitate initial stages of translational research (73). Furthermore, costs 
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and time investments may be reduced by streamlined facilities related to GMP production 
of the compound, toxicology studies and conducting clinical studies (74). 
A better understanding how radioligands compare to each other could also facilitate earlier 
testing in patients as this could allow research efforts to concentrate on the most promising 
radioligand. Head-to head comparison of radioligands are rarely performed however, 
whereas a large number of inflammation targeted radioligands are explored preclinically. 
More direct preclinical comparison will better identify the most promising radioligands 
for further clinical translation. The study described in Chapter 6 and by Rinne et al. and 
Borchert et al. (55,72) are good examples of studies in which radioligands are compared. 
2. Mechanistic insight into radioligand behaviour. It is currently not known how radioligands 
are taken up in plaque. Plaque tissue is highly heterogenic, generally rich in lipids, and 
located in high blood flow environments. Many radioligands in vivo often only get a few 
passes along the plaque, in which the radioligand has to be able to penetrate the tissue. 
Also, they should not stick to non-target molecules and remain attached to the receptor 
long enough to enable visualization.
Basic knowledge on how the radioligands behave is often based on biodistribution studies. 
Although these avenues of research are needed to understand radioligand behaviour, 
new options in research are worthwhile to pursue. More fundamental research into the 
behaviour of radioligands can be facilitated by new in vitro models. For example, organ on a 
chip models mimic aspects of organ physiology in an in vitro setting. Adapting such systems 
to plaque biology could provide a controlled environment in which radioligand behaviour 
could be examined. 
Combining nuclear imaging methods with other imaging modalities may further facilitate 
fundamental research. For example, optical imaging works by imaging bioluminescence 
or visualizing a fluorescently-labelled compound. Although dual labelling a ligand with 
a radionuclide and a fluorescent label can severely affect binding affinity, in the case of 
conserved binding affinity this could allow careful and real-time monitoring of how the 
ligands interact with plaque tissue, similar to cell tracking studies. Currently unanswered 
questions on how ligands enter plaque by visualizing a fluorescent label, which portion 
of applied ligand passes plaque tissue by counting a radionuclide attached to the ligand, 
or how ligands bind to cells in plaque could be answered with such methods. This could 
complement in vivo models and existing in vitro models.
3. Multimodality imaging. Early recognition of plaques (before rupture) is the ultimate goal 
of this research. This would significantly improve ‘personalised medicine’ or ‘precision 
medicine’, individually tailoring a timely start of pharmacological intervention and to 
stratify the risk of developing symptomatic disease. Also, assessment of coronary plaque 
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inflammation can aid the development and validation of new anti-atherosclerotic or anti-
inflammatory therapies. Based on our research, it is most likely that nuclear imaging of 
(focal) inflammation in patients with atherosclerosis will consist of a hybrid scan, which 
combines multiple radioligands in SPECT or PET with CT or possibly MRI (current imaging 
approaches are discussed by Adamson et al. (4)). From this single combined scan, a clinician 
may be able to identify the location of the plaque, degree of calcification and deduce 
the plaque morphology including degree of specific inflammatory activity. Dual isotope 
imaging with multiple radioligand imaging with SPECT (Chapter 5), or PET (as discussed by 
Walrand et al. (75)), could facilitate this process. The individual and societal consequences of 
such a tool could be substantial. 
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Hart- en vaatziekten vormen de hoofdoorzaak van sterfte wereldwijd (1,17); verdere toename 
van hart- en vaatziekten wordt verwacht vanwege de stijging in levensduur en toename 
van westerse levensstijl in Aziatische en Zuid-Amerikaanse landen (18). Aderverkalking, of 
atherosclerose, is de voornaamste oorzaak van hartaanvallen en beroertes (6), goede diagnose 
en behandeling van atherosclerotische plaques is daarom van groot belang. Innovatie 
detectiemethodes zoals besproken in dit proefschrift zijn daarom van belang om de behandeling 
van de verouderende populatie te sturen. Daarnaast is onderzoek naar de toepassing van deze 
methoden, zoals besproken in de laatste hoofdstukken van dit proefschrift, van cruciaal belang 
om nieuwe technologieën zo spoedig mogelijk naar de kliniek te brengen.
Beeldvorming met behulp van radionucliden wordt al geruime tijd toegepast, en het gebruik 
van nucleaire beeldvormingstechnieken neemt toe. De toepassing is gestandaardiseerd en 
ruime kennis over scantechnieken is aanwezig. Echter, de invoering van nieuwe technieken 
vereist nieuwe perspectieven, nieuwe benaderingen, en veelal nieuwe expertise. In Hoofdstuk 
2 behandelen we een aantal belangrijke overwegingen bij de beeldvorming van atherosclerose 
in kleine dieren. Bij nieuwe state-of-the-art beeldvormingsmethoden die de hoogst haalbare 
gevoeligheid en nauwkeurigheid nastreven, is het van belang om bij elk aspect van de 
beeldvorming de hoogste standaard na te streven. Ten eerste bespraken we de noodzaak en 
het potentieel van nieuwe beeldvormingsmethoden in atherosclerose. Vervolgens refereren 
we aar verdere bronnen over diermodellen van atherosclerose en bespreken we de verschillen 
tussen atherosclerose in muis en mens met betrekking tot plaque samenstelling en locatie, en 
verschillen tussen immuuncellen. We behandelen technische overwegingen zoals kwantificatie 
en beeldreconstructie en beschrijven mogelijkheden in hybride beeldvorming en verschillen 
tussen klinische en preklinische PET en SPECT. We bespreken ook welke eigenschappen van 
belang zijn bij de ontwikkeling van nieuwe radioliganden. Ten slotte geven we onze visie op de 
toekomst van preklinische beeldvorming. 
In Hoofdstukken 3 en 4 rapporteren we over twee nieuwe beeldvormingsmethoden voor 
plaque detectie. In Hoofdstuk 3 beschrijven we het onderzoek naar het nieuwe radioligand 
[111In]In-DANBIRT, dat bindt aan Leukocyte Function associated Antigen-1 (LFA-1). Dit is een zeer 
aantrekkelijk doelwit voor beeldvorming, omdat het aanwezig is op alle witte bloedcellen. Terwijl 
veel studies radioliganden onderzoeken die gericht zijn op macrofagen, kan beeldvorming van 
LFA-1 een completer beeld geven van de mate van ontsteking in plaque. Dit is van belang 
omdat naast macrofagen veel andere ontstekingscellen zoals neutrofielen, dendritische cellen, 
en monocyten een rol spelen in het ontstaan en de destabilisatie van plaques (19-22). In deze 
studie vonden we dat [111In]In-DANBIRT succesvol gebruikt kan worden om in vivo plaque te 
detecteren in atherosclerotische muizen met een hoge target to background ratio (TBR) en 
hoge nauwkeurigheid. Door middel van immuunhistochemie van macrofagen vonden we ook 
dat binding van [111In]In-DANBIRT en expressie van LFA-1 co-lokaliseerde met gebieden van 
ontsteking. Dit resultaat vonden we zowel in menselijk weefsel als in weefsel van muizen, we 
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concludeerden dat [111In]In-DANBIRT veel potentie heeft voor in vivo detectie van plaque in 
humane studies.
Hoofdstuk 4 beschrijft onze studie naar [111In]In-DOTA-JR11, een radioligand dat bindt aan 
Somatostatine Receptor subtype 2 (SST2). SST2 komt sterk tot expressie op macrofagen en kan 
daarom gebruikt worden als doelwit voor de detectie van ontsteking in plaques. In eerdere 
beeldvormingsstudies in patiënten met SST2 als doelwit detecteerde onderzoekers plaque in 
vivo in de kransslagaders (23) en halsslagaders (24) met het radioligand [68Ga]Ga-[DOTA,Tyr3]-
octreotate (DOTATATE). DOTA-JR11 is echter een andere type radioligand dan DOTATATE. 
Recent onderzoek (zie (25) voor een overzicht) toonde aan dat DOTA-JR11 een vijf tot tien keer 
hogere opname heeft dan DOTATATE in tumorweefsel. Vanwege deze hogere opname wilden 
we onderzoeken of DOTA-JR11 ook gebruikt kan worden in atherosclerose, omdat bij hogere 
opname minder zwaar ontstoken plaques potentieel ook gedetecteerd zouden kunnen 
worden. We onderzochten de haalbaarheid van plaque beeldvorming met [111In]In-DOTA-
JR11 in vivo in atherosclerotische muizen en in plaque weefsel van muizen en mensen. In vivo 
vonden we hoge opname van [111In]In-DOTA-JR11, hetgeen in ex vivo en in vitro experimenten 
bevestigd werd. Vanwege de eerdere successen van atherosclerose beeldvorming met SST2-
bindende radioliganden zijn patiëntenstudies met DOTA-JR11 of met een directe vergelijking 
van DOTA-JR11 en DOTATATE nu wenselijk.
Nucleaire beeldvorming wordt voornamelijk uitgevoerd met één radioligand per beeld-
vormingsprocedure. Het gebruik van meerdere radioliganden kan verschillende aspecten 
van ziekte in beeld brengen en daarmee meer informatie geven over welke plaque wel of 
niet behandeling behoeft. In Hoofdstuk 5 beschrijven we ons onderzoek dat een eerste stap 
in deze richting zette. In dit onderzoek verkenden we een beeldvormingsprotocol dat beide 
visualisatie-doelwitten besproken in Hoofdstuk 3 en 4 combineert. Zowel beeldvorming van 
LFA-1 als SST2 heeft veel potentie om atherosclerose te visualiseren in de kliniek. Een (S)PE(C)
T/CT-protocol dat onderscheid kan maken tussen stabiele plaque via CT, ontstoken plaque 
via LFA-1 beeldvorming en plaque-kwetsbaarheid door CT, LFA-1- en SST2-beeldvorming te 
combineren zou zeer waardevol zijn. Ten eerste vonden we dat dit protocol haalbaar is in 
humaan plaqueweefsel in vitro. We vonden ook dat [111In]In-DANBIRT bindt aan alle types 
plaque, met hogere binding aan onstabiele plaques. Verder observeerden we dat, terwijl 
visualisatie van SST2 mogelijk was met [
99mTc]Tc-[N4,Asp
0,Tyr3]-octreotate ([99mTc]Tc-Demotate 
2), er geen significante verschillen in opname waren tussen verschillende soorten plaques. 
Tenslotte vonden we dat radioligand-opname co-lokaliseerde met immuunhistochemie voor 
LFA-1 en SST2. Deze resultaten wijzen erop dat beeldvorming met meerdere radioliganden 
mogelijk is in atherosclerose en dat [111In]In-DANBIRT gebruikt kan worden om onderscheid 
te maken tussen verschillende plaque types, terwijl dit niet kon met het radioligand dat SST2 
visualiseerde in deze experimenten. Op basis van deze data is [111In]In-DANBIRT aantrekkelijk 
voor zowel detectie van plaque als om onderscheid te maken tussen plaque-types.
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Naast plaquedetectie is onderscheid tussen verschillende plaque-types een belangrijk doel in 
de cardiologie. In Hoofdstuk 6 beschrijven we de studie waarin we onderzochten of dit mogelijk 
is met een aantal veelbelovende radioliganden. We onderzochten [111In]In-DOTATATE en [111In]
In-DOTA-JR11 voor beeldvorming van SST2, [
111In]In-DANBIRT voor LFA-1, [67Ga]Ga-Pentixafor 
voor chemokine CXC motif receptor type 4 (CXCR4), en [111In]In-EC0800 voor de Folate Receptor 
(FR). We gebruikten in vitro autoradiografie en immuunhistochemie om de aanwezigheid van 
deze beeldvormingsdoelwitten en de binding van de radioliganden daaraan te onderzoeken 
in verschillen plaque-types. [111In]In-DANBIRT en [111In]In-EC0800 hadden de hoogste binding 
in alle plaque-types en zijn daarmee potentieel het meest bruikbaar voor plaquedetectie in 
de kliniek. We vonden ook dat deze radioliganden de hoogste binding hadden in kwetsbare 
plaques, [111In]In-EC0800 had echter ook hoge binding in stabiele plaques. [111In]In-DOTATATE, 
[111In]In-DOTA-JR11, en [67Ga]Ga-Pentixafor hadden vergelijkbare patronen van binding, al 
was de mate van binding lager dan van de andere radioliganden. Echter, binding van [111In]
In-DOTA-JR11 en [67Ga]Ga-Pentixafor verschilde ook tussen stabiele en kwetsbare plaques, wat 
potentieel het onderscheid tussen deze plaquetypes mogelijk maakt. Om de onderzoeksvraag 
in Hoofdstuk 4 en 5 aan te vullen onderzochten we beide radioliganden besproken in Hoofdstuk 
4. We vonden een veel hogere mate van binding van [111In]In-DOTA-JR11 ten opzichte van [111In]
In-DOTATATE. De resultaten van radioliganden met SST2 als doelwit verschilde met de resultaten 
voor dit doelwit in Hoofdstuk 5, wat suggereert dat de verschillen tussen deze radioliganden 
en de experimentele procedures verder onderzocht moeten worden.
Ondanks dat in vitro binding niet direct in vivo opname voorspelt, verwachten we dat 
plaquedetectie de meeste kans van slagen heeft door gebruik van radioliganden die LFA-1 
en FR als doelwit hebben. Onderscheid tussen plaquetypes kan het best gedaan worden met 
radioliganden met CXCR4 of SST2 als doelwit. Het gebruik van meerdere radioliganden kan 
daarom van belang zijn voor goede diagnose van atherosclerose. 
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way. I will for sure remember this throughout my further career. Thank you for making this 
PhD-project possible.
I am also grateful to the leaders of the departments I was able to work in: Ton van der Steen, 
Fred Verzijlbergen, and Gabriel Krestin. The leadership you provided allowed strong research 
groups to flourish, groups in which I was able to perform research on a high level. Thank you.
Importantly, I want to thank my collaborators. Thomas van Wolleghem, Gulce Kaplan, Ruoyu 
Xing, Erik de Blois, Marcel Segbers, Jeffrey Norenberg, Hilary Barrett, and Jan de Swart. I believe 
you are all great scientists and it was a joy to work with you. I especially like to thank Hilary, 
your arrival and presence in the EMC made our ‘team’ of nuclear cardiology double in size :) 
providing a much-needed sparring partner and immensely speeding up my project. Also, to 
Marcel I like to express my special thanks. You are very knowledgeable, and fully contributed to 
each project you worked on. 
I also thank all of my colleagues. Colleagues from Biomedical Engineering, Nuclear Medicine, 
Radiology, MILabs, and all the other colleagues I was fortunate enough to meet through 
committees, courses, congresses and chance encounters. Although I thoroughly enjoyed the 
science in my project, you guys made my time memorable, thank you. 
I also like to dedicate a line to my girlfriend, Pinar. Thank you for your help. I still think you’re 
weird.
Finally, and most importantly, I would like to stress that we ‘stand on the shoulders of giants’ 
(attributed to Bernard of Chartres), not only in work but also as people. Throughout my life 
I had the privilege to be around people who were inspiring, people who gave great advice, 
and people who outright helped me at the moment I needed it most, often without knowing 
it myself. These people helped shape my character. Without these admirable ‘giants’ I would 
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not have started this project, let alone finish it. Foremost amongst these are my parents; The 
stability, peace, and core values you provided are the main contributor to making this PhD 
project successful, and I can never thank you enough. If writing a thesis can be called a success, 
I dedicate it fully to them and the other giants. I am grateful for all I have received.
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Scientific contributions
Journal papers
Meester E.J., de Blois E., Krenning, B.J., van der Steen A.F.W., van Gaalen K., Bernsen M.R., de Jong 
M., van der Heiden K. Autoradiographical assessment of inflammation-targeting radioligands 
for atherosclerosis imaging: potential for plaque phenotype identification
European Journal of Nuclear Medicine and Molecular Imaging, in review
Barret H.E., Meester E.J., Van Gaalen, K., Van der Heiden, K., Krenning, B.J., Beekman. FJ., de Blois, 
E., de Swart, J., Verhagen, H., Maina, T., Nock, B.A., Norenberg, J.P., de Jong, M., Gijsen, F., Bernsen, 
M.R. Imaging of Inflammatory Cellular Protagonists in Human Atherosclerosis: A Dual-Isotope 
SPECT Approach 
European Journal of Nuclear Medicine and Molecular Imaging, 2020. doi: 10.1007/s00259-020-
04776-0
Sari G., Meester E.J., van der Zee L.C., Wouters K., van Lennep J.R., Peppelenbosch M., Boonstra 
A., van der Heiden K., Mulder M.M.T., Vanwolleghem T. A mouse model of humanized liver 
shows a human-like lipid profile, but does not form atherosclerotic plaque after western type 
diet.
Biochemical and Biphysical Research Communications. 2020. 524(2):510-515 doi:10.1016/j.
bbrc.2020.01.067
Meester E.J., Krenning B.J., de Blois E., de Jong M., van der Steen A.F.W., Bernsen M.R., van der 
Heiden K. Imaging inflammation in atherosclerotic plaques, targeting SST2 with [
111In]In-DOTA-
JR11 Journal of Nuclear Cardiology. 2020. doi: 10.1007/s12350-020-02046-y
Meester E.J, B. J. Krenning, J. de Swart, M. Segbers, H. E. Barrett, M. R. Bernsen, K. Van der Heiden, 
Marion de Jong. Perspectives on Small Animal Radionuclide Imaging in Atherosclerosis; 
Challenges and Advances
Frontiers in Medicine. 2019. 6: 39. doi: 10.3389/fmed.2019.00039
Xing R., Moerman A.M., Ridwan R.Y., van Gaalen K., Meester E.J., van der Steen A.F.W., Evans 
P.C., Gijsen F.J.H., Van der Heiden K. The Effect of the Heart Rate Lowering Drug Ivabradine on 
Hemodynamics in Atherosclerotic Mice
Nature Scientific Reports. 2018. 8(1): 14014. doi: 10.1038/s41598-018-32458-3.
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 133
133A Road to Improved Diagnostics – Imaging Inflammatory Cells in Atherosclerosis | 
Meester E.J., B. J. Krenning, R. H. de Blois, J. P. Norenberg, M. de Jong, M. R. Bernsen, K. Van der 
Heiden. Imaging of Atherosclerosis, Targeting LFA-1 on Inflammatory Cells with 111In-DANBIRT
Journal of Nuclear Cardiology. 2018. 26(5): 1697-1704. doi: 10.1007/s12350-018-1244-5.
Conference presentations
 − NKRV Workshop, Utrecht, The Netherlands, 28/06/2019 (Invited talk) 
 − MoMaDc lunch, Rotterdam, The Netherlands 04/04/2019 (Invited talk) 
 − EMIM, Glasgow, Great Britain, 21/03/2019 (Poster presentation) 
 − MolMed day, Rotterdam, The Netherlands, 14/03/2019 (Pitch)
 − NKRV Workshop, Rotterdam, The Netherlands, 25/01/19 (Pitch and poster presentation, won 
second presentation prize) 
 − EANM, Dusseldorf, Germany, 13/10/2018 (E-poster presentation) 
 − MILabs meeting, Utrecht, The Netherlands, 13/10/2018 (Oral presentation)
 − Translational Cardiovascular Research Meeting, Utrecht, The Netherlands, 29/06/18 (Oral 
presentation)
 − COEUR day, Rotterdam, The Netherlands, 05/04/2018 (Oral presentation)
 − MolMed day, Rotterdam, The Netherlands, 15/03/2018 (Oral presentation, won presentation 
prize)
 − MILabs meeting, Utrecht, The Netherlands, 17/11/2017 (Oral presentation)
 − EANM, Vienna, Austria, 25/05/2017 (Oral presentation)
 − COEUR day, Rotterdam, The Netherlands, 19/04/2017 (Oral presentation, won presentation 
prize)
 − Shear Stress Symposium, Rotterdam, The Netherlands, 04-05/04/2017 (Poster presentation) 
 − Famelab,The Netherlands, Rotterdam 16/03/2017, Delft 03/04/2019 
 − MolMed day, Rotterdam, The Netherlands, 21/03/2017 (Poster presentation) 
 − Imaging Infections and Inflammation, Rome, Italy, 13/04/2016 (Poster presentation) 
 − COEUR day, Rotterdam, The Netherlands, 13/04/2016 
 − Papendal Course, Arnhem, The Netherlands, 15/10/2015 (Oral presentation)
 − Papendal Course, Arnhem, The Netherlands, 14/10/2015 (Poster presentation) 
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Biography
Eric Jan Meester was born on June 10th, 1990 in Delft, The Netherlands. He completed high 
school (HAVO, 2007. VWO, 2009) at Stanislas College Delft. 
After high school, he studied Biology at Leiden University from 2009 to 2012. He participated 
in Honours College during his bachelor, obtained his high school teaching certificate, and 
completed multiple research projects. One project was partly performed in Caen, France, 
under supervision of Professor Hans Metz, where he investigated coastal species diversity in 
tide pools. A second project was performed with Professor Hans Witte, Dr. Hans Slabbekoorn, 
and Dr. Niels Bouton. In this project he investigated the effect on anthropogenic noise on fish 
behaviour, physiology, and morphology. 
After his bachelor studies, Eric performed his Master studies in Biology at the same university 
from 2012 to 2014. During his masters he was elected to join the Leiden Leadership 
Programme, a prestigious Honours programme for excellent students. During this programme 
he performed a project on policy development in the Leiden University Medical Center (LUMC). 
During his master, he conducted two research projects. His first project, under supervision of 
Professor Peter Klinkhamer and Dr. Martina Stang at the department of plant phytochemistry 
and physiology, was partly located in Alicante, Spain. He investigated the interaction of floral 
shape and nectar composition in relation to flower visitation by pollinators. His second research 
project was conducted at the LUMC under supervision of Professor Michael Richardson and 
Professor Robert Klinkhamer. This project focussed on the embryological development of the 
crocodile cardiac ventricular septum.
Eric started his PhD research in 2015 at the Erasmus MC in Rotterdam at the departments of 
Cardiology: Biomedical Engineering and Radiology & Nuclear Medicine. In collaboration with 
Professor Marion de Jong, Dr. Kim van der Heiden, Dr. Boudewijn Krenning, and Dr. Monique 
Bernsen he performed the research projects documented in this thesis. During this period, he 
received 3 prizes for scientific presentations, obtained 2 travel grants, and gave 2 invited talks. 
Moreover, he co-founded the Dutch young Molecular Imaging Community (DyMIC).
After his PhD studies, Eric pursued a postdoctoral position at the Erasmus MC in 2019, 
department of Radiology & Nuclear Medicine, in collaboration with Dr. Simone Dalm.
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 136
548249-L-bw-Meester
Processed on: 17-9-2020 PDF page: 137
137A Road to Improved Diagnostics – Imaging Inflammatory Cells in Atherosclerosis | 
PhD portfolio
Name PhD student:  Eric Meester
Erasmus MC Departments:  Cardiology, Biomedical Engineering
  Radiology & Nuclear Medicine
Promotor: Marion de Jong
Supervisor: Kim van der Heiden
Courses Year ECTS
5a course 2015 1
5b course 2015 1
Pubmed course: systematic literature retrieval 1 2015 0.5
Pubmed course: systematic literature retrieval 2 2015 0.5
Cardiovascular pharmacology course 2015 0.5
AMIE course 2015 1.4
Excel course: basics 2016 0.5
Excel course: advanced 2016 0.5
Microscopic image analysis course 2017 1
Presenting course 2017 0.5
Scientific intergrity course 2017 0.4
MILabs training VECTOR 2017 0.3
MILabs training Pmod 2017 0.3
Stress management course 2017 2
PET training 2018 3
Biomedical English Writing Course 2018 2.5
Subtotal 15.8
Seminars and workshops Year ECTS
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Postdoc network workshop: Funding 2015 0.2
Postdoc network workshop: networking 2017 0.2
Postdoc network workshop 2017 0.2
COEUR lecture: DNA damage in CVD 2017 0.1
People in Science workshop 2018 0.2
Monocyte lunch 2019 0.1
Postdoc network 2019 0.2
Subtotal 1.2
Conferences and symposia Year ECTS
Shear stress symposium 2015 0.6
Papendal course 2015 2
Translational research symposium 2016 0.3
Innovation for health 2016 0.3
MolMed day 2016 0.3
EMIM Utrecht 2016 1
COEUR day 2016 0.15
AMIE/OIC symposium 2016 0.3
Congress on imaging inflammation and infectious diseases 2016 0.6
MolMed day 2017 0.3
Shear Stress symposium 2017 0.6
COEUR day 2017 0.15
Imaging Research on the move 2017 0.2
PhD day EMC 2017 0.15
Young@heart talent day 2017 0.3
EANM Vienna 2017 1.2
Monocytes symposium 2017 0.2
MILabs user meeting 2017 0.2
Conferences and symposia (Continued) Year ECTS
Imaging Research on the move 2017 0.2
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Chameleon event 2018 0.3
Molmed day 2018 0.3
Translational research symposium 2018 0.3
PhD day EMC 2018 0.15
Imaging Research on the move 2018 0.2
MIlabs user meeting 2018 0.2
EANM Dusseldorf 2018 1.2
Young@heart talent day 2018 0.3
Monocyte symposium 2018 0.2
NKRV workshop 2019 0.5
MolMed day 2019 0.3
EMIM Glasgow 2019 1
COEUR symposium 2019 0.1
NKRV workshop 2019 0.5
Subtotal 15
Presentations Year ECTS
50+ talks at different congresses, workshops, groups 2015-2019 5
Teaching Year ECTS
Supervision of MLO student 2018 0.1
Other Year ECTS
exCOEURsion: Philips 2017 0.3
exCOEURsion: Leiden Biosciencepark 2018 0.3
Total 37.8
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Eric J. Meester obtained his Master of science 
degree in Biology. He performed his doctoral 
studies at the Erasmus MC in Rotterdam, the 
results of which are discussed in this thesis.
Atherosclerosis is a complex and multi-factorial 
disease. Proper diagnosis is crucial for timely and 
adequate treatment, but remains difficult with current 
techniques. In this thesis, novel diagnostic methods 
developed with state of the art techniques are 
discussed.
